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Abbreviation list: 
17a-HSD: 17a-hydroxysteroid-dehydrogenase 
3a-HSD: 3a-hydroxysteroid-dehydrogenase 
3b-HSD: 3b- hydroxysteroid-dehydrogenase 
5a-R: 5a-reductase 
AC: adenylate cyclase 
AGO: argonaute 
AKT: serine/threonine kinase 1 
ALLO: allopregnanolone, 5a-pregnan-3a-ol-20-one, also named tetrahydroprogesterone 
AMOTL2: angiomotin like-2 
AREG: amphiregulin 
AXL: AXL receptor tyrosine kinase 
BDNF: brain derived neurotrophic factor 
BP: biological process 
BPE: bovine pituitary extract 
BRN2/POU3F2: POU domain, class 3, transcription factor 2 
BSA: bovine serum albumin 
C-JUN: jun proto-oncogene 
CA: cytosolic carbonic anhydrase 
cAMP: cyclic adenosine monophosphate 
Caspr: contactin associated protein 
CC: cellular compartment 
CCL2 or MCP-1: chemokine ligand 2 
CCR: coiled-coil region 
CDC42: cell division cycle 
CGRP: calcitonin gene-related peptide 
CMT: Charcot-Marie-tooth 
CNP: 2’,3’-cyclic nucleotide 3’ phosphodiesterase 
CNS: central nervous system 
CRB: crumbs homolog 
CREB-2: transcription factor 2 
CTGF: connective tissue growth factor 
CX32: connexin 32 
CYR61: cysteine rich protein 
DAPI: 40,6-diamidino-2-phenylindole 
DCHS: dachsous protein 
DHH: Dicer 
DMEM: Dulbecco modified eagle medium 
DP: dehydroprogesterone 
DRG: dorsal root ganglia 
EAAC1: excitatory amino acid transporter 1 
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ECl: equilibrium potential of Cl- anions 
EDTA: ethylendiaminetetraacetic acid 
EGF: epidermal like growth factor 
EMF: electromagnetic field 
ERBB: tyrosine kinase epidermal growth factor receptors 
ERK: RAS/RAF/MEK/ERK 
ERK/MAPK: extracellular regulated MAPK/mitogen-activated protein kinase 1 
FAK: focal adhesion kinase 
FAT: transmembrane cadherine proteins 
FBS: fetal bovine serum 
FERM: 4.1 ezrin, radixin, moesin domain 
GABA-A R: GABA-A receptor 
GABA-B R: GABA-B receptor 
GABA-T: GABA transaminase enzyme 
GABA: g-aminobutyric acid 
GAD: glutamic acid decarboxylase 
GDNF: glialcell line derived neurotrophic factor 
GFAP: glial fibrillary acidic protein 
GLI2: GLI-Kruppel family member 
GO: gene ontology 
GPCRs: G-protein coupled receptors 
GPR126: g protein coupled receptor G6 
HMN: motor neuropathies 
HMSN: hereditary motor and sensory neuropathies 
HPN: hereditary peripheral neuropathies 
HPO: Hippo 
HRS: hepatocyte growth factor-regulated tyrosine kinase substrate 
HSN: sensory neuropathies 
IFL: immunofluorescence 
IGF-1: insulin growth factor-1 
IGF-2: insulin-like growth factor 2 
IL-1a and b: interleukin 1a and b 
KCC2: K+/Cl- cotransporter 
KCTD: potassium channel tetramerization domain 
KO: knock out 
KROX20: myelin transcription factor Egr2 
L1: L1 cell adhesion molecule 
LATS1/2: large tumor suppressor 
LIF: leukemia inhibitory factor 
LOH: loss of heterozygosity 
MAG: myelin-associated glycoprotein 
MAP4Ks: mitogen-activated protein kinase 
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MATS: mob as tumor suppressor 
MBP: myelin basic protein 
Merlin-1: Merlin isoform 1 
Merlin-2: Merlin isofrom 2 
MF: molecular fucntion 
miRNAs: microRNAs 
MOB1a/b: MOB kinase activator 
mPR: putative membrane progesterone receptor 
MRI: magnetic resonance imaging 
MST1/2: serine/threonine kinase ½ 
mTOR: mechanistic target of rapamycin 
NCAM: neural cell adhesion molecule 
NF: neurofilament 
NF1: neurofibromatosis type 1 
NF2: neurofibromatosis type 2 
Nf2: neurofibromin 2 
NGF: nerve growth factor 
NHERF: the solute carrier family 9, sodium/hydrogen exchanger, member 3 regulator 1 
NICD: Notch intracellular domain 
NKCCl: Na+/K+/Cl- cotransporter 
NOTCH: neurogenic locus notch homolog protein 
NRG1: neuregulin 1 
NT3: neurotrophin 3 
OCT6/POU3F: POU domain, class 3, transcription factor 1 
OLs: oligodendrocytes 
OPCs: OL-precursors cell 
P: progesterone 
P0: myelin protein zero 
P450SCC: P450 cholesterol side-chain cleavage enzyme 
p75NTR: nerve growth factor receptor 
PAK: p-21 activated kinase 
PBS: phosphate buffer saline 
PDGF-B: platelet derived growth factor, b polypeptide 
PDK1: 3-phosphoinositide dependent protein kianse-1 
PI3K: phosphoinositide-3-kinase regulatory subunit 1 
PIP2: phosphatidylinositol diphosphate 
PIP3: phosphatidylinositol triphosphate 
PKA: protein kinase A 
PKC: protein kinase C 
PLP: proteolipid protein 
PMP22: peripheral myelin protein 22 
PN: peripheral neuropathies 
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pNF: plexiform neurofibroma 
PNS: peripheral nervous system 
PP2: 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)-pyrazolil-[3,4-d]pyrimidine 
RISC: RNA-induced silencing complex 
SAV: salvador 
SAV1: salvador family WW domain containing protein 1 
SCHIP1: schwannomin interacting protein 1 
SCPs: SC-precursors 
SCs: schwann cells 
SKP1/ASK1: E3 Ubiquitin ligase SCF complex subunit 
SOX10: SRY-Box10 
SOX2: SRY-Box2 
SRC: non-receptor tyrosine kinase Src 
SSADH: succinate semi-aldehyde dehydrogenase enzyme 
TAOK1/2/3: TAO kinases 
TEAD: TEA domain transcription factor 
TERT: telomerase reverse transcriptase 
TGF-b: transforming growth factor-b 
TNF-a: tumor necrosis factor-b 
VEGF: vascular endothelial growth factor 
VGATs: vescicular GABA transporters 
VGLL4: vestigial like family member 4 
Vm: resting membrane potential of the neuron 
VS: vestibular schwannoma 
Wnt: wingless 
Wnt1: proto-oncogene protein 1 
Wts: warts 
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The origin, development and maturation of Schwann cells (SCs), the main glial cells of 
the peripheral nervous system (PNS), are a set of complicated and intriguing processes. 
These multifactorial processes take place following a precise and unique coordination 
between different molecules and intracellular signaling, that interact with a complex of 
endogenous and exogenous signals. Among these, there are integrins, neuregulins, 
growth factors, hormones, neurotransmitters and intracellular pathway, including 
protein kinase A and protein kinase C (PKA and PKC), serine/threonine kinase 1 
(AKT), extracellular regulated MAPK/mitogen-activated protein kinase 1 
(ERK/MAPK), Hippo, mechanistic target of rapamycin (mTOR), etc.  
This thesis is focused on some novel intracellular signaling pathways involved in the 
SCs development and maturation, from their origin to the acquisition of the myelinating 
or repairing phenotype. 
The first part of the thesis focuses on a proto-oncogene, the non-receptor tyrosine kinase 
SRC (SRC), and the focal adhesion kinase (FAK), which are intermediate pathways 
known to play a role in the control of adhesion, motility, and migration of SCs. It has 
been investigated whether these pathways are regulated by allopregnanolone (ALLO), 
a neuroactive steroid of peculiar interest for the control of SCs maturation. 
The second part of this thesis focuses on the study of the Hippo signaling pathway, 
known to be a key regulator of proliferation, apoptosis, control of organ size and 
crucial for cancer proliferation. Hippo pathway has been studied in SCs, where it is 
linked to Merlin (an oncosuppressor protein) and Yes associated protein/tafazzin 
(YAP/TAZ) factors. Interestingly, these mechanisms were responsive to physical and 
environmental challenges. 
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Lastly, the third part of this thesis move on studying the role of the g-aminobutyric acid 
(GABA) system in the control of peripheral myelination. In particular, the whole 
expression profile was investigated in conditional knock out mice for the B1 subunit of 
the GABA-B receptor (GABA-B R), with a specific deletion in SCs. By the use of 
microarray technology, several genes resulted up- or downregulated in SCs, opening 
new perspectives on the possible targets downstream GABA-B R in SCs. 
Overall, these results highlight new aspects of the SCs biology, shedding light on 
unraveled mechanisms and underlying their importance in the development and 
maturation of these specialized cells of the PNS. This may be of pharmacological and 
therapeutically interest, in order to identify reliable approaches for the treatment of 
PNS diseases. 
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Peripheral nervous system (PNS) 
The nervous system is the morpho-functional unit deputed to process internal and 
external stimuli and elaborate a response. It is formed by neuronal and glial cells, blood 
vessels and connective tissue. From an anatomically point of view the nervous system 
can be divided in central and PNS. 
The central nervous system (CNS) is subdivided in encephalon and spinal cord. The 
role of the CNS is to control physiological functions, like analysis and coordination of 
sensory input and motor output, learning, memory and emotions. CNS cooperates with 
the PNS for the implementation of these functions, indeed the two systems are 
anatomically and functionally linked.  
The most important function of the PNS is the correlation of the CNS with the 
periphery. PNS is able to collect the input data from the internal and external parts of 
the body and conduct them to the CNS through the sensitive fibers. When the 
information reaches the CNS, is elaborated and the response is forwarded to the 
periphery through the efferent (Marieb and Hoehn, 2007). 
From a physiological point of view, the PNS can be divided into somatic and 
autonomous. The somatic PNS controls the voluntary movements, originates from 
the spinal cord gray matter and make contact with the skeletal muscles. The 
autonomous PNS, indeed, controls involuntary body responses, making contact with 
heart, visceral smooth muscles, blood vessels and glands. The autonomous PNS is 
subdivided in sympathetic and parasympathetic, both originating from the spinal 
cord. More in detail, the sympathetic portion originates from the turaco-lumbar tract 
of the spinal cord, whereas the parasympathetic originates from the cervical and 
sacral portions. Fundamentally, these systems exert opposite actions. The 
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sympathetic branches is activated under stressful conditions (the “fight or flight” 
response), while the parasympathetic is prevalent in resting situations (Marieb and 
Hoehn, 2007; Monk et al., 2015). 
Peripheral nerves and dorsal root ganglia (DRG) neurons  
Nerves are the anatomical structure responsible for signal conduction and are formed 
by fascicles of nerve fibers in the PNS. Nerves are subdivided in sensitive, motor and 
mixed nerves, which are the most common in the PNS. Nerve fibers are formed by two 
components, the axon (the cellular process originating from the neuronal soma) and the 
myelin sheath formed by SCs, the glial cells of the PNS, that wrap the nerves in a 1:1 
ratio (Figure 1). These are myelinated fibers, characterized by a significant fast 
conductance. Fibers that do not present the myelin sheath are named unmyelinated 
fibers, and are organized in structures known as Remak bundles, in which a single SC 
embraces multiple axons, without myelin formation (Monk et al., 2015). 
Macroscopically, a nerve appears like a white cordlike structure with a thickness 
between 0.2 µM and 1 cm. Peripheral nerves are formed by myelinated and 
unmyelinated fibers grouped to form fascicles, separated by connective laminae that 
also contain arterial, venous and lymphatic vessels. Single fascicles may be formed only 
by myelinated or unmyelinated fibers, or have both type. There are three different 
connective sheaths in a nerve. Single fibers are wrapped by a sheath called 
endoneurium; group of fibers are enveloped by the perineurium, while the epineurium 
ensheaths the whole nerve (Marieb and Hoehn, 2007). 
In adult nerve the endoneurium is linked to the basal lamina and surround the axon-SC 
unit, forming a stable structure where nerve fibers are sustained and protected by 
collagen and vascularized extracellular matrix. Moreover, the perineurium, is a 
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multilayer cellular tube that protect the endoneurium and the nerve fibers from 
exogenous cells and molecules (Marieb and Hoehn, 2007). Around E16 in rat (E14 in 
mouse), the compact structure changes fast, the extracellular spaces containing collagen 
appear within the nerve and fibroblast and blood vessels appear; SCs basal lamina starts 
its formation, and it becomes evident the perineurial sheath (Peltonen et al., 2013). 
Contacts between axons and glia at the nodes of Ranvier are established by SCs 
microvilli, which are enriched in F-actin (Oguievetskaia and Goutebroze, 2006). 
 
Figure 1 Nerve anatomy. 
The cell bodies of neurons forming the motor/effector nerves are located in the ventral 
horns of the spinal cord. Sensitive nerves cell bodies, indeed, are grouped in anatomical 
structures called DRG, located outside the spinal cord, paravertebral to the spinal 
column (Figure 2). 
DRG are formed by pseudounipolar neurons, presenting a single axon originating from 
the soma that divides in a “T” shape, respectively in a peripheral and central branch. 
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The peripheral branch represents the afferent fiber, which collect information from the 
periphery, while the central branch projects to the dorsal horn of the spinal cord. In the 
DRG the neuronal soma is surrounded by satellite cells, a particular type of glial cells. 
They are homologous to SCs and their function is to give structural and biochemical 
support to DRG neurons (Hanani, 2005). 
As better detailed below, SCs in the PNS are deputed to the formation of the myelin 
sheath, and are fundamental in the development of the PNS (Feltri et al., 2016), SCs are 
important for the complex cross-talk with neurons (Faroni et al., 2014b; Salzer, 2015; 
Taveggia, 2016), and address the nerve regeneration process following an injury (Glenn 
and Talbot, 2013; Faroni et al., 2015). 
 
Figure 2 Cross-sectional anatomy of the spinal cord. 
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Schwann cell origin, development and myelination 
SCs derive from the migratory cells of the neural crest in a well-defined sequence of 
events (Figure 3). During early vertebrate development, neural crest cells delaminate 
from the dorsal-most region of the neural tube and these progenitor cells are migratory 
and proliferative. They migrate throughout the embryo to originate to different cell 
types, including cardiac cells, melanocytes, skeletal and connective tissue components 
of the head, neurons and glia of the PNS (Monk et al., 2015). SCs derive from ventrally 
migrating neural crest cells, like sympathetic neurons and DRG neurons (Le Douarin 
and Teillet, 1973).  
Most SCs arise from neural crest derived SC precursors (SCPs), these, like neural crest 
cells, are migratory and proliferative. SCPs co-migrate with axons in the developing 
PNS and are dependent upon axonal signals for survival (Dong et al., 1995). SCPs are 
the cells representing the first stage of the SC lineage (Jessen et al., 2015).  
 
Figure 3 Schwann cell lineage – “Schwann Cells: Development and Role in Nerve Repair” Jessen KR, Mirsky R, 
Lloyd AC  - Cold Spring Harb Perspect Biol. 2015. 
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At E16, SCPs differentiate to immature SCs. By E18 in rat (E16 in mouse), nerves are 
formed of axon-SCs bundles embedded in extracellular matrix containing collagen and 
blood vessels. SCPs disappear from developing nerves when immature SCs and 
fibroblast appear (Wanner et al., 2006). SCPs show different phenotype from neural 
crest cells and immature SCs, because they express glial differentiation markers and 
other factors and respond differently to survival, proliferation and differentiation signals 
(Jessen and Mirsky, 2005; Woodhoo and Sommer, 2008). Furthermore, SCPs and 
immature SCs are different also in term of molecular expression, since the increase in 
S100 (a specific marker of SCs) mRNA levels is the characteristic of the immature SCs. 
Moreover, also the survival regulation is different. In fact, SCPs are acutely dependent 
on the axon-associated survival signal neuregulin 1 (NRG1) type III. NRG1 is neuronal 
epidermal like growth factor (EGF), interacting with its tyrosine kinase epidermal 
growth factor (ERBB) receptors, that are  key regulators of myelination (Chen et al., 
2003, 2006; Michailov et al., 2004; Taveggia et al., 2005). NRG1/ERBB signaling is 
the main determinant of SC development, mediating the activation of the 
phosphoinositide-3-kinase regulatory subunit 1 (PI3K) pathway and leading to the 
phosphorylation of 3-phosphoinositide dependent protein kinase-1(PDK1), which in 
turn converts phosphatidylinositol diphosphate (PIP2) to phosphatidylinositol 
triphosphate (PIP3), then activating AKT (Castelnovo et al., 2017). NRG1 is also 
expressed on axons, embryonic DRG and motor neurons, suggesting that either the 
survival of SCPs, the generation of SCs or the myelination are crucially dependent on 
axonal NRG1. Moreover, other factors like the neurogenic locus notch homolog protein 
(NOTCH) are important for SCs. Notch is a transmembrane receptor which is activated 
from ligand, is cleaved and form an intracellular domain (NICD), that acts like a 
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transcriptional regulator (Boerboom et al., 2017). Notch controls SC proliferation and 
promotes the generation of immature SCs from SCPs in vivo but can acts also as a 
negative regulator of myelination. NOTCH activation and/or over-activation leads to 
premature or delayed myelin formation, respectively. The inhibition of NOTCH 
signaling in adult mice delayed myelin breakdown following a nerve lesion (Woodhoo 
et al., 2009). NOTCH, and JAGGED 1 (an activator of NOTCH), are expressed on 
embryonic axons and also present in SCPs. In mice with genetic ablation of Notch1, SC 
generation from precursors is delayed, whereas SCs appear more rapidly in mice where 
NOTCH signaling is enhanced (Woodhoo et al., 2009). Moreover, Notch, in rat nerves 
after injury improves nerve regeneration and functional recovery (Wang et al., 2015). 
SCPs may also control nerve fasciculation and are implicated in the survival of 
developing DRG and motor neurons (Jessen et al., 2015). Glial cells are determinant on 
establishing nerve architecture, indeed they confer to the axons the capability to 
elongate correctly for long distances, creating group of axons that originate nerve fibers.  
From E15/16 or E17/18, respectively in mice and rats, SCPs start to differentiate in SCs. 
SCs envelop groups of axons, forming irregular axon/SCs columns, which are covered 
by the basal lamina and surrounded by extracellular matrix (Webster et al., 1973). Some 
days later (E19/20 in mice and E21 in rats), the process of radial sorting starts and single 
axons become individually ensheathed by SCs. This event is a prerequisite for the 
myelination process, that takes place in case of large axons (Jessen et al., 2015). 
By the radial sorting process, SCs separate axons destined to become myelinated from 
those that will remain in non-myelinated Remak bundles. Moreover, SCs send signal to 
perineurial cells and other nerve components to promote their differentiation. These 
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events lead to the formation of the mature final nerve (myelinated fibers and Remak 
bundles), surrounded by extracellular matrix and blood vessels (Monk et al., 2015). 
During the embryogenesis, the conversion from SCPs and immature SCs is accompanied 
by an increase in proliferation, which in turn is correlated to an intracellular cyclic 
adenosine monophosphate (cAMP) level increase (Stewart et al., 1993; Chernousov et 
al., 2008). The increase in cAMP levels is due to the interaction between G-protein 
coupled receptors (GPCRs) and specific agonist; the activation of a Gas protein 
(stimulatory), activates the adenylate cyclase (AC), determining a signal transduction 
cascade which increase cAMP levels (Arthur-Farraj et al., 2011; Mogha et al., 2013).  
SCs proliferation in vivo is driven by axon-associated signals, for example NOTCH and 
NRG1, soluble signals, such as transforming growth factor-b (TGF-b) and signals 
derived from the basal lamina, such as laminin. In particular, laminin is the principal 
component of the basal lamina, linking SCs through an interaction with dystroglycan 
and b1 integrin receptor. Laminin promotes SC proliferation in vivo, indeed the lack of 
the cell division cycle 42 (CDC42), the downstream effector of the b1 integrin, reduces 
proliferation of immature SCs (Feltri et al., 2008). 
SCs possess NOTCH receptors and axons show the presence of NOTCH ligands. 
Interestingly, NOTCH is a potent inducer of SCs division in vitro, indeed, in neonatal 
nerve, NOTCH signaling inactivation results in a substantial reduction in DNA 
synthesis and SCs numbers (Woodhoo et al., 2009). These findings demonstrate that 
NOTCH signaling, drives SCs proliferation in developing nerves (Woodhoo et al., 
2009). TGF-b is another important factor that regulates SCs proliferation. TGF-b 
stimulates SCs proliferation in culture, even though, in some other conditions induces 
apoptosis (Ridley et al., 1989; Einheber et al., 1995; Parkinson et al., 2001). TGF-b is 
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able to drive SC division in perinatal nerves (D’Antonio et al., 2006). The function of 
TGF-b may be to amplify the proliferation of cells with tight axonal contact, or to 
suppress supernumerary cells with less effective axonal affiliation (D’Antonio et al., 
2006). 
SC survival changes rapidly when SCs modify their phenotype from SCPs to SCs. 
Survival of SCPs depends on axon-associated signals (Dong et al., 1995), whereas 
immature SCs, even in embryonic nerves, bypass this strict axon dependence by the 
intervention of autocrine survival circuits, including insulin-like growth factor 2 (IGF-
2), neurotrophin 3 (NT3), platelet derived growth factor, b polypeptide (PDGF-B), 
leukemia inhibitory factor (LIF), and lysophosphatidic acid (Jessen and Mirsky, 2005). 
In vitro, cell survival is density dependent, and SCs population survives upon the loss 
of axonal contact in damaged nerves.  
Notably, injury increases SC apoptosis in neonatal nerves but also in the adult (Grinspan 
et al., 1996; Syroid et al., 2000), suggesting a persistent but decreasing contribution of 
axonal signals to SC survival. After longer periods, however, most of the SCs not in 
contact with injured nerves die (Höke, 2006; Sulaiman and Gordon, 2009).  
There are different types of peripheral nerve injury. The axonotmesis where the axons 
are disrupted but the connective tissue and the SCs containing basal lamina tubes 
remain intact. The neurotmesis, in which axons, connective sheaths and basal lamina 
tubes are interrupted (Figure 4). Functional recovery after nerve cut is generally 
incomplete, especially in human. The reason is ascribed to targeting errors made by 
regenerating axons between the proximal and distal nerve stumps, leading to incorrect 
target innervation (Witzel et al., 2005; Höke, 2006). Distal to the injury the axons die, 
triggering a series of events involving SCs, macrophages, and other cells. This 
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process, called “Wallerian degeneration”, is complex and build up a specific 
environment to support the survival of injured neurons, axon regrowth and guidance 
(Chen et al., 2007; Allodi et al., 2012).  
 
 
Figure 4 Types of peripheral nerve injury. From the top to the bottom, a peripheral nerve without damage, the 
axonotmesis, where only the axon is disrupted, and the neurotmesis where the axon, connective sheath and basal 
lamina tube are interrupted. (Seddon, 1942). 
The regeneration process depends on SCs plasticity during the repair process. The 
injury-induced changes in SCs during Wallerian degeneration has been characterized 
as a kind of dedifferentiation (Chen et al., 2007), although they are commonly described 
as a kind of activation (Armstrong et al., 2007; Campana, 2007; Webber and Zochodne, 
2010; Allodi et al., 2012). Early after the injury, SCs response to the axonal interruption 
and rapidly develop radical phenotypic changes. This suggest that injured axons alert 
SCs of axon death, even though the mechanism behind this process should be further 
elucidated (D’Antonio et al., 2006; Martini et al., 2008). The first step consists of the 
reversion of the myelin differentiation process. In fact, molecules like L1 cell adhesion 
molecule (L1), neural cell adhesion molecule (NCAM), nerve growth factor receptor 
(p75NTR), glial fibrillary acidic protein (GFAP), that characterize SCs before 
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myelination, are down-regulated. Also other myelin associated genes are decreased, for 
example the key myelin transcription factor Egr2 (KROX20), enzymes of cholesterol 
sysnthesis, structural proteins such as myelin protein zero (P0), myelin basic protein 
(MBP), and membrane-associated proteins like myelin-associated glycoprotein (MAG) 
and periaxin (Jessen and Mirsky, 2008). In this context, the SCs present an increased 
expression of some neurotrophic factors such as glial cell line derived neurotrophic 
factor (GDNF), artemin, brain derived neurotrophic factor (BDNF), Nt3, nerve growth 
factor (NGF), vascular endothelial growth factor (VEGF), and pleiotrophin, that 
promote the survival of injured neurons and axonal elongation (Fontana et al., 2012; 
Brushart et al., 2013). Moreover, in the distal stump, the SCs upregulate the expression 
of cytokines including tumor necrosis factor (TNF)-a, LIF, interleukin (IL)-1a and b, 
and chemokine ligand 2 (CCL2 or MCP-1), which need to recruit macrophages. 
Furthermore, SCs activate a myelin breakdown through an autophagic process. All 
together, these events promote the nerve repair through the activation of different 
pathways. 
The formation of regeneration tracks is an important component of the SCs-activated 
injury response. The SCs flattened around axons and adopt an elongated bipolar 
morphology, allowing them to align and constitute a SCs column, that forms track from 
the injury site to the nerve target areas. Recently it was proposed that the repairing 
program originate a novel SCs phenotype, specifically committed to participate to the 
nerve repair, the so-called “repair SCs”. This conversion, from immature SCs to repair 
SCs is regulated by the transcription factor c-jun, activated in SCs of injured nerves 
(Arthur-Farraj et al., 2012).  
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The GABA-ergic system in the PNS  
GABA is the main inhibitory neurotransmitter in the mature nervous system. GABA is 
synthesized from glutamate by two glutamic acid decarboxylase (GAD) enzymes of 
different molecular weight: GAD67 and GAD65 (Pinal and Tobin, 1998). GAD67 is 
localized in the cytoplasm, mostly in the neuronal soma, and it provides basal level of 
GABA synthesis. Conversely, GAD65 is preferentially located in the axonal terminal 
and it provides additional supply of GABA in condition of metabolic need (Asada et 
al., 1997; Kash et al., 1997; Namchuk et al., 1997). When GABA is synthesized, 
vescicular GABA transporters (VGATs) are embedded in presynaptic vescicular 
membranes and use the electrochemical gradient to shuffle and pack GABA into small 
synaptic vesicles (Roth and Draguhn, 2012). Upon fusion of the synaptic vesicles to the 
cell membrane, due to incoming action potentials, GABA is released in the synaptic cleft 
where it interacts with ionotropic GABA-A, GABA-C, or metabotropic GABA-B Rs. 
Finally, the catabolism of GABA depends on GABA transaminase enzyme (GABA-T) 
and succinate semi-aldehyde dehydrogenase enzyme (SSADH), which convert GABA 
into intermediates of the Krebs cycle and substrates for new glutamate synthesis. Like 
other neurotransmitters in the CNS, GABA is produced and released also by glial cells, 
mainly astrocytes. In the hippocampus, for example, GABA released by astrocytes 
regulates neuronal activity and tonic inhibition (Jow et al.; Liu et al., 2000). 
Furthermore, in the developing CNS, mechanism involving the activation of GABA 
receptors influence different processes such as neuronal or glial precursor proliferation, 
differentiation, and migration (Barres et al., 1990; al-Dahan and Thalmann, 1996; Ben-
Ari, 2002; McCarthy et al., 2002; Owens and Kriegstein, 2002). 
27 
 
Recently, SCs were shown to express a functional GABAergic system that can 
participate in the control of SC development and myelination (Magnaghi et al., 2004b, 
2006a), but also in the regulation of the sensory and nociceptive functions (Procacci et 
al., 2012; Faroni et al., 2014a). 
The GABA-A and GABA-B Rs 
GABA-A ionotropic R (GABA-A R) is a ligand-gated ion channel. In the adult CNS, 
upon activation, the GABA-A receptor selectively produce an inward flux of Cl- 
resulting in the hyperpolarization of the neuron. This causes an inhibitory effect on the 
neurotransmission, diminishing the chance of a successful action potential occurrence. 
The reversal potential of the GABA-A-mediated inhibitory postsynaptic potential 
(IPSP) is -70 mV. The magnitude and direction of the ionic current through GABA-A 
Rs depends on its driving force, defined as the difference between the electrochemical 
equilibrium potential of Cl- anions. Depending by a positive or negative difference, a 
flux of Cl- anions through the plasma membrane may occur. This determines a change 
in the membrane potential of the neuron. 
In neurons, two main chloride cotransporters are responsible for setting intracellular 
Cl- concentration [Cl-]i. The Na+/K+/Cl- cotransporter NKCCl (Blaesse et al., 2009), 
which imports Cl- into the neuron, and the K+/Cl- cotransporter KCC2, which exports 
Cl- out (Rivera et al., 1999; Sernagor et al., 2010; Kahle et al., 2013). When the 
equilibrium potential of Cl- anions (ECl) is close to the resting membrane potential of 
the neuron (Vm), GABA will exert its inhibitory action by a shunting inhibitory 
mechanism. Indeed, the local increase in membrane GABA-A Rs conductance will 
“hold” the neuron at the ECl, reducing the amplitude of subsequent excitatory 
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postsynaptic potentials (following Ohm’s law) and thus shunting any excitatory input 
(Gonzalez-Burgos et al., 2011). 
The Cl--extruding K+-Cl- cotransporter KCC2, and the cytosolic carbonic anhydrase 
(CA) isoform CAVII control the efficacy and qualitative nature of GABAergic 
transmission during development (Rivera et al., 1999). In rat hippocampal pyramidal 
neurons, a step up-regulation of KCC2 accounts for the “developmental switch”, 
which converts depolarizing and excitatory GABA responses of immature neurons to 
classical hyperpolarizing inhibition, by the end of the second postnatal week. Around 
postnatal day 12 (P12), a consistent increase in intrapyramidal CAVII expression 
takes place, promoting excitatory responses evoked by intense GABAergic activity 
(Rivera et al., 1999). 
GABA-A R present binding sites for GABA and other specific molecules such as 
muscimol (GABA-A R agonist), gaboxadol (GABA-A R agonist), and bicuculline 
(GABA-A R antagonist). However the receptor contains a number of different allosteric 
binding sites, which indirectly modulate the activity of the receptor. The allosteric sites 
are targets of various other drugs including, benzodiazepines, neuroactive steroids 
(discussed below), barbiturates, ethanol, anesthetics and picrotoxin (Figure 5).  
Nineteen genes encoding for different GABA-A subunits have been identified: α1–α6, 
β1–β3, γ1–γ3, δ, ε, π, q, ρ1–ρ3. The subunit composition of major GABA-A Rs is 
2a/2b/¡ (the last being sometimes substituted by d or e) (Boileau et al., 2005), although 
also the existence of other receptor combination was expected (Jones and Henderson, 
2007). Functional GABA-A Rs, with the pharmacological profile of native receptors, 
are formed by pentameric assembly of 2a/2b/¡2, where the a and b subunits can be 
either identical or different. The ¡2 subunit can be substituted by ¡1 or ¡3 subunits 
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(present et low levels and/or with a restricted expression pattern) or by d, and possibly 
e, subunits (Fritschy and Panzanelli, 2014).  
 
Figure 5 GABA-A R structure - https://www.organicnewsroom.com/gaba-supplement/ 
GABA-A Rs can be distinguished in classical ‘phasic’ GABA-A Rs (responsible for 
synaptic current) and ‘tonic’ GABA-A Rs, usually extra-synaptic receptors activated by 
low concentrations of local GABA. Extra-synaptic GABA-A Rs are composed of 
receptor subunits that generate persistent inhibition, and are pharmacologically and 
functionally distinct from their synaptic counterparts (Belelli et al., 2009).  
Therefore, GABA-A Rs are classified in synaptic and extra-synaptic (depending on 
their cellular localization). The synaptic one is located at the post-synaptic terminals 
and mediate the classic phasic inhibition upon GABA release from pre-synaptic 
terminals. The post-synaptic one is localized beside synaptic position, and are 
responsible for tonic GABA-A inhibition (Belelli et al., 2009; Reddy, 2011). 
In general, α1, α2, α3 and γ2 subunits typically form synaptic receptors, while α4, α5, 
α6 are typical extra-synaptic receptor subunits, with the γ2 subunit often substituted by 
δ (Fritschy and Panzanelli, 2014). The β subunits composition is not particularly 
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indicative of the synaptic or extra-synaptic nature of the receptor. Although that GABA-
A R with δ subunit is mostly extra-synaptic, not all extra-synaptic receptors present the 
δ subunit (Belelli et al., 2009). 
The GABA-B R was initially identified by Bowery and colleagues in the 80’s. It is a 
transmembrane metabotropic receptor for GABA that is not responsive to the GABA-
A R antagonist bicuculline, evidencing a different structure. GABA-B R is specifically 
activated by GABA and baclofen but it is not coupled to Cl- channels, or responsive to 
barbiturates or benzodiazepines. The GABA-B R is a GPCR, which activation induces 
the activation of a Gi/G0 protein, generally linked to the AC enzyme, therefore its 
activation induces an inhibition and the reduction of cAMP levels, with decrease of 
PKA activity. As a consequence, the GABA-B may give a reduction of the 
phosphorylation levels of PKA-dependent transcription factors (Steiger et al., 2004) and 
kinases (Gassmann and Bettler, 2012). It can also stimulates the opening of the K+ 
channels which brings the neuron closer to the equilibrium potential of K+. This reduces 
the frequencies of action potentials, in turn reducing neurotransmitter release. 
Moreover, GABA-B R can also reduce cell Ca2+ conductance.  
GABA-B Rs are present at pre- and post-synaptic level. At the pre-synaptic level play 
an important role in the regulation of the release of other  neurotransmitters, including 
GABA itself, therefore are called auto-receptors; when localized on other terminals they 
are called hetero-receptors (Gassmann and Bettler, 2012). Two subtypes of GABA-B 
R, called GABA-B1 and GABA-B2 have been identified (Jones et al., 1998; Kaupmann 
et al., 1998; White et al., 1998; Kuner et al., 1999) (Figure 6). The B1 has been 
characterized in 3 different isoforms, B1 a,b and c (Kaupmann et al., 1997; Gassmann 
and Bettler, 2012) by different groups. Different studies demonstrated that the 
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heterodimer GABA-B1/GABA-B2, within the two subunits in a 1:1 stoichiometric 
ratio, is the active form (Charles et al., 2003). The GABA-B1 subunit is responsible for 
binding GABA and other specific ligands, while GABA-B2 is responsible for  the 
receptor functions, for the co-regulation of some transcription factors [eg. activating 
transcription factor 2 (CREB-2)] and for the interaction with auxillary subunits 
belonging to the potassium channel tetramerization domain (KCTD) family, which bind 
to GABA-B2 on the cell surface (Charles et al., 2003; Gassmann and Bettler, 2012). 
The interaction of the two subunits takes place at the carboxyl-terminal domains, 
leading to the formation of a a-helix coiled coin structure. 
 
Figure 6 GABA-B R structure “Regulation of neuronal GABA-B receptor functions by subunit composition” 
Gassmann M, Bettler B - Nature Reviews Neuroscience 2012 
GABA-B Rs are present in the neuronal compartment of the spinal cord white matter 
(Margeta-Mitrovic et al., 1999; Charles et al., 2001) and their expression is higher in 
the laminae I–IV of the dorsal horn (Price et al., 1987; Towers et al., 2000), where it 
co-localize with GAD enzymes and primary afferent fibers (Barber et al., 1978; Todd 
and Lochhead, 1990; Waldvogel et al., 1990). GABA-B R isoforms were also found 
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in pig nodose ganglion cells, in autonomic nerve terminals, in peripheral axons and in 
rat DRG (Bowery et al., 1981; Towers et al., 2000; Zagorodnyuk et al., 2002). 
Different studies confirmed the presence of GABA-B R not only in the neuronal, but 
also in the glial compartment (Kuhn et al., 2004; Kozlov et al., 2006; Serrano et al., 
2006; Luyt et al., 2007). 
The role of the GABA Rs in the PNS 
First observations in the 80’s demonstrated that in the PNS, myelinated and 
unmyelinated fibers, possess GABA Rs and GABA carriers (Brown and Marsh, 1978; 
Brown et al., 1979; Morris et al., 1983; Olsen et al., 1984). In the 1984, Gavrilovic and 
colleagues, demonstrated the uptake of GABA by high-affinity mechanism, in purified 
SCs maintained in cell culture in vitro for up to six months (Gavrilovic et al., 1984). 
Recently, the presence of GABA-A and B Rs has been shown in PNS, particularly in 
the SCs, which possess the functional receptors and are able to synthesize GABA 
(Magnaghi et al., 2010). In the sciatic nerve of adult male rats were a2, a3, b1, b2 and 
b3 and SCs showed similar expression levels. The mRNA studies were confirmed with 
immunohistochemical analysis on rat SCs. The presence of GABA-B isoforms 1a, 1b, 
1c and 2 mRNAs, was demonstrated not only in the brain (Margeta-Mitrovic et al., 
1999; Towers et al., 2000; Charles et al., 2001) but also in the sciatic nerve and in the 
SCs (Magnaghi et al., 2004b, 2008a).  
The GABAergic system is implicated in the regulation of the myelination process. It 
has a physiological role in SCs, influencing the expression of myelin protein. For 
example, peripheral myelin protein 22 (PMP22), which is one of the most important 
proteins required for the maintenance of the multilamellar structure of the peripheral 
myelin (Quarles, 1997; Bronstein, 2000). May be under the control of the GABA-A R. 
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In fact, it has been demonstrated that a prolonged exposure of SCs to the GABA-A 
agonist muscimol, in the range of micromolar concentration, exerted a stimulatory 
effect on the mRNA level of PMP22 (Magnaghi et al., 2001; Melcangi et al., 2005). 
This might be of pharmacological interest, since alterations in the gene encoding for the 
PMP22 are associated with a set of hereditary peripheral neuropathies, for example the 
Charcot-Marie-Tooth type – 1A (see below) (Naef and Suter, 1998)  
SCs cultures, the GABA-B R is negatively coupled to the AC system (Magnaghi et al., 
2004a), in fact baclofen (GABA-B R specific agonist) counteracted the forskolin (a 
cAMP- inducing agent) -induced proliferation of SCs in vitro and control the mRNA 
levels of specific peripheral myelin proteins, such as glycoprotein P0, PMP22, myelin 
MAG and Connexin32 (CX32) (Magnaghi et al., 2004a).  
The importance of the GABAergic system in the peripheral myelination emerges also 
from in vivo studies. Mice with an ablation of the B1 subunit of the GABA-B R show 
an increase in the P0 and PMP22 levels, nerve with smaller fibers and thinner myelin 
sheaths with and increased number of fibers with small axons and irregular profiles. 
These mice have an increased number of calcitonin gene-related peptide (CGRP)-
positive fibers and decreased number of neurofilament (NF)-200-positive fibers in 
peripheral nerves. Moreover, the nerve cell bodies of lumbar DRG are smaller in 
GABA-B1 -/- mice. The total knock out mice show also a gait alterations and signs of 
hyperalgesia, without allodynia (Magnaghi et al., 2008b).  
Interestingly, GABA-B Rs may regulate myelination and nociception in the PNS, 
through the important contribution of the glial compartment. In fact conditional knock 
out mice, bearing the deletion of the B1 subunit of the GABA-B R, only in SCs, present 
signs of SCs degeneration, tomacula, fractured myelin and partial uncompaction of 
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myelin. These mice present also an increase in the number of irregular fibers, suggesting 
a SCs-autonomous modulatory action of GABA-B1 (Faroni et al., 2014a). The deletion 
of the receptor in SCs can affect also the neuronal compartment demonstrating also 
signs of SCs non-autonomous mechanism. Indeed, number and size of small fibers were 
changed with an increase in small unmyelinated axons. These mice also shown an 
altered pain sensitivity with signs of hyperalgesia and allodynia (Faroni et al., 2014a). 
Neuroactive steroids 
The first observation on the existence of neuroactive steroids comes from the 80’s, when 
the novel concept that hormonal steroids may be synthesized de novo or metabolized in 
the nervous system, was introduced. In the 1997, Baulieu and colleagues coined the 
term “neurosteroids” in order to define these molecule (Baulieu, 1997). The central and 
peripheral glial cells, which are fundamental for the regulation of neuronal activity, are 
also able to synthesize neurosteroids (Celotti et al., 1992; Melcangi et al., 2001). Glial 
cells possess the complex machinery required for the production of steroids: the P450 
cholesterol side-chain cleavage enzyme (P450SCC), the 17a-hydroxysteroid-
dehydrogenase (17a-HSD), the 3b- hydroxysteroid-dehydrogenase (3b-HSD) and 
some others. These cells also convert them into neuroactive metabolites (Mellon et al., 
2001). Indeed, the enzymatic complex formed by the 5a-reductase (5a-R) and the 3a-
hydroxysteroid-dehydrogenase (3a-HSD) enzymes deputed to convert the native 
steroids into the 5a3a active metabolites, has been characterized in several areas of the 
mammalian brain (Steckelbroeck et al., 2001) and in the PNS (Melcangi et al., 1990, 
1992, 1999; Celotti et al., 1992)  
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Evidences from the literature show that the metabolism of neuroactive steroids may be 
relevant for the differentiation of glial cells (Gago et al., 2004). The presence of 5a-R-
3a-HSD enzymatic complex in oligodendrocytes (OLs) and SCs suggests that the 
locally formed neuroactive steroids might play a crucial role in the process of 
myelination (Melcangi et al., 1988, 2001; Martini et al., 2003) 
The 5a-pregnan-3a-ol-20-one, also named tetrahydroprogesterone or ALLO is the 
main hormonal steroid that was originally shown to act as neurosteroids. It is 
synthesized through the action of the 5aR-3a-HSD, which converts progesterone (P) 
into dehydroprogesterone (DHP) and subsequently, via a bidirectional reaction, into 
ALLO. The ALLO actions on the neuronal compartment were demonstrated, although 
other observations suggested important roles for ALLO also in glial cells. 
ALLO is a potent modulator of the GABA-A R (Lambert et al., 1995). In fact, the most 
important “non-classic”, non-genomic action of neuroactive steroids is represented by 
ALLO’s activation of GABA-A R (Lambert et al., 2003). The mechanism of action on 
GABA-A receptor is concentration dependent. In a low nanomolar concentration ALLO 
acts allosterically, enhancing the action of the natural ligand GABA, while at higher 
concentration (micromolar range) ALLO directly gates the GABA-A R channel 
complex (Puia et al., 1990). Interestingly, neuroactive steroids might also influence the 
activation of the GABA-A R acting indirectly, for example, on the regulation of its 
subunits (Maguire and Mody, 2009). ALLO is also able to interact with protein kinase 
or phosphatases, which in turn act on GABA-A subunits altering the entire receptor 
functions (Belelli and Lambert, 2005). Furthermore, the phosphorylation of GABA-A 
R by PKC influences the sensitivity to neuroactive steroids (Vergnano et al., 2007). 
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Neuroactive steroids proved particularly active in the PNS. Progestagens stimulate the 
expression of specific peripheral myelin proteins, such as P0 and the PMP22, in the 
sciatic nerve of rats (Melcangi et al., 2000; Magnaghi et al., 2001), they reduce myelin 
abnormalities and fibers loss in aged sciatic nerve (Azcoitia et al., 2003), and promote 
re-myelination after a lesion (Melcangi et al., 2000).  
In particular, ALLO is one of the most important neuroactive steroids involved in these 
actions, likely through autocrine mechanisms (Figure 7). ALLO controls the expression 
of different GABA-B R subunits, via a GABA-A mediated mechanism (Magnaghi et 
al., 2006b; Magnaghi, 2007). GABA-B subunits expression may be differently 
influenced, by ALLO either via a GABA-A-mediated mechanism, or by its precursors 
P and/or DHP after 5a-R-3a-HSD conversion into ALLO (Faroni and Magnaghi, 
2011). Moreover, acting through an autocrine loop, ALLO increased the levels of 
GAD67 in SCs, thus stimulating GABA synthesis and providing the natural ligand for 
GABA-A R (Magnaghi et al., 2010). This hypothesis was corroborated by the 
observation that SCs possess functionally active glutamate uptake system, able to 
provide glutamate as a precursor for the GABA synthesis (Perego et al., 2012). SCs, in 
fact, possess the excitatory amino acid transporter 1 (EAAC1) in the plasma membrane 
and in intracellular vesicular compartments of the endocytic recycling pathway. 
  
37 
 
 
 
Figure 7 Schematic representation showing ALLO, GABA and its receptors acting in a bidirectional cross-talk 
between neurons and SC. GABA, comes from neurons or produced directly by SC affect the paracrine cross-talk 
between these cells. Extracellular GABA acts on GABA-B Rs on the SCs surface, decreasing their proliferation, 
leading to a decrease in cAMP levels and a reduction in myelin protein expression, prompt the SCs to start the 
differentiation. ALLO, allosterically activates the GABA-A R on the SC surface. This modulate the expression and 
the responsiveness of the GABA-B R, and in turn its desensitization. Meanwhile, ALLO stimulates the SC 
proliferation inducing other genomic effects such as the increase of myelin proteins and the increase of GAD enzymes 
levels. This trigger an autocrine mechanism involving enhanced cAMP levels and PKA pathway. The balance of 
GABA-A or GABA-B Rs on SCs, by ALLO and GABA, starts an autocrine loop relevant for the control of SC 
proliferation and differentiation. (Faroni and Magnaghi, 2011).  
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The SRC/FAK pathway in the PNS 
Proto-oncogene tyrosine-protein kinase SRC is a non-receptor tyrosine kinase protein 
encoded by the SRC gene in humans. The SRC protein is a tyrosine-protein kinase 
whose activity can be inhibited by phosphorylation of its terminal. An elevated level of 
SRC tyrosine kinase is suggested to be linked to cancer progression by promoting other 
signals. SRC and SRC-family protein-tyrosine kinases are regulatory proteins that play 
key roles in cell differentiation, motility, proliferation, and survival.  
From the N- to C-terminus, SRC contains an N-terminal 14-carbon myristoyl group, an 
SH4 domain, a unique segment, an SH3 domain, an SH2 domain, a protein-tyrosine 
kinase domain, and a C-terminal regulatory tail (Roskoski, 2005) (Figure 8).  
 
Figure 8 The SRC family kinases (SFKs). (A) domain organization of SFKs; (B) Amino acid alignments of N-
terminal unique domain, activation loop and C-terminal and regulatory tail in SFKs. (Okada, 2012). 
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SRC is expressed ubiquitously in vertebrate cells. However, brain, osteoclasts, and 
platelets express higher levels of this protein than most other cells (Brown and Cooper, 
1996). In fibroblasts, SRC is bound to endosomes, perinuclear membranes, secretory 
vesicles, and the cytoplasmic side of the plasma membrane, where it can interact with 
different growth factors and integrin receptors (Brown and Cooper, 1996; Thomas and 
Brugge, 1997). The expression of high levels of SRC in platelets (anucleate cells) and 
in neurons (which are post mitotic) indicates that SRC participates in processes other 
than cell division (Roskoski, 2005).  
Mutations in this gene could be involved in the malignant progression of colon cancer. The 
activation of the SRC pathway has been observed in tumors from colon, liver, lung, breast 
and the pancreas. A common mechanism is that there are genetic mutations that result in 
the increased activity or in the overexpression of the SRC (Irby and Yeatman, 2002). 
The SRC tyrosine kinase plays an important role in modulating signaling from growth 
factors receptor, integrin and steroid receptors (Fu and Simoncini, 2008). In fact, in c-
SRC deficient mice, the loss of the SRC tyrosine kinase correlates with some defects 
on ductal development as well as in uterine and ovarian development (Kim et al., 2005). 
Moreover, Src is highly enriched in the developing axons of the CNS and in the PNS 
(Sorge et al., 1984; Fults et al., 1985), indeed SRC is an important signal transducer for 
axonal outgrowth. Regarding the PNS, SRC is a crucial component of different signal 
transduction pathways implicated in a wide range of cellular processes, including cell 
growth, migration and differentiation (Zhao et al., 2003). In the PNS, the Src activity is 
also increased during nerve regeneration (Le Beau et al., 1991; Zhao et al., 2003), 
whereas it enhances axon-SCs contact for nerve regrowth. Indeed, SRC is also 
expressed in the SCs distal from a nerve injury, decreasing with restoration of axon-
40 
 
SCs cross-talk (Zhao et al., 2003). However, the molecular mechanism at the bases of 
the Src functions in SCs has not been fully understood.  
FAK is another non-receptor protein tyrosine kinase, controlling cell motility and the 
turnover of focal adhesion sites (Flamini et al., 2011; Sanchez et al., 2011). FAK is 
relevant for SCs, being involved in regulating their proliferation, survival and 
differentiation (Grove et al., 2007; Grove and Brophy, 2014). When FAK is not present, 
developing SCs proliferate poorly, sort axons inefficiently and do not myelinate 
peripheral nerves. However, FAK is unnecessary for adult SCs, neither for myelin 
maintenance nor for re-myelination after sciatic nerve lesion (Grove and Brophy, 2014). 
FAK is required in vivo for the process of radial sorting (Grove et al., 2007). FAK 
phosphorylation at Tyr397 is an early event, serving to expose a docking site for Src 
(Schaller et al., 1994; Xing et al., 1994). Then, SRC phosphorylates some sites in FAK, 
promoting optimal FAK activation (Calalb et al., 1995). Therefore, the mutual 
phosphorylation between SRC and FAK might be a mechanism of potentiation of SCs 
cellular processes (Figure 9). 
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Figure 9 FAK as a signal integrator. FAK acts to integrate signals from extracellular cues, such and growth-factor 
receptors and integrins, and from the upstream Src-family kinases, to control and coordinate adhesion dynamics/cell 
migration with survival signaling. FAK binds to integrin and Src to growth factor receptors and they bind to each 
other. (McLean et al., 2005) 
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The Hippo pathway in the PNS  
General concepts 
Hippo is an intracellular signaling pathway playing a crucial role in cell proliferation, 
apoptosis, differentiation and development (Bae et al., 2017). Hippo acts inducing the 
phosphorylation of downstream factors. For instance, the phosphorylation cascades of 
Hippo core components [e.g. Hippo (HPO) , salvador (SAV), warts (WTS), and MOB 
as tumor suppressor (MATS) in Drosophila and serine/threonine kinase (MST1/2), 
Salvador family WW domain containing protein 1 (SAV1), large tumor suppressor 
(LATS1/2), and MOB kinase activator (MOB1a/b) in mammals] inhibit the activation 
of some transcriptional co-activators such as Yorkie (YKI), YAP, and TAZ. These co-
activators function as transcription factors along with TEA domain transcription factor 
(TEAD) in the nucleus, increasing the expression of target genes, as connective tissue 
growth factor (CTGF), cysteine rich protein 61 (CYR61), AXL receptor tyrosine kinase 
(AXL), and Survivin. Therefore, YAP and TAZ are the major effectors of the Hippo 
signaling cascade. Indeed, the phosphorylation of YAP and TAZ and activation of 
LATS kinase are regulated by multiple mechanisms (Bae et al., 2017). 
The Hippo pathway was initially identified in Drosophila Melanogaster, albeit, in the 
recent year, most of the studies focused on its function and regulation in mammalian 
cells. In mammals, the core of the Hippo pathway is a kinase cascade in which the 
mammalian MST1/2 phosphorylate and activate LATS1/2. From a physiological point 
of view, the output of this cascade is to restrict the activities of YAP and TAZ. The 
activation of YAP and TAZ leads to their translocation into the nucleus, where they 
bind the TEAD transcription factor family, inducing the expression of genes involved 
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in cell proliferation, survival, and migration (Meng et al., 2016). TEAD1-4 is a 
sequence-specific transcription factors that mediate the main transcriptional output of 
the Hippo pathway in mammalian cells (Zhao et al., 2008). Moreover, TEAD1-4 is able 
to bind vestigial like family member 4 (VGLL4) in the nucleus, functioning as a 
transcriptional repressors; this produces the dissociation of VGLL4 from TEAD1-4 and 
the activation of TEAD-mediated gene transcription, promoting tissue growth and 
inhibition of apoptosis (Koontz et al., 2013). 
More in detail (Figure 10), the mechanism of the Hippo kinase cascade can be initiated 
by TAO kinases (TAOK1/2/3), which phosphorylate MST1/2, thereby leading to its 
activation (Boggiano et al., 2011; Poon et al., 2011). There are also evidence that 
MST1/2 can auto-phosphorylate (Praskova et al., 2004). Activation of this loop of 
phosphorylations is improved by MST1/2 dimerization (Glantschnig et al., 2002), but 
is also possible that MST1/2 activation can be promoted without requiring upstream 
kinases. Consequently, active MST1/2 phosphorylate SAV1 and MOB1A/B (Callus et 
al., 2006; Praskova et al., 2008), two scaffold proteins that assist MST1/2 in the 
recruitment and phosphorylation of LATS1/2 (Hergovich et al., 2006; Yin et al., 2013). 
Contemporary to MST1/2, two groups of mitogen-activated protein kinase (MAP4Ks), 
MAP4K1/2/3/5 and MAP4K4/6/7, can also directly phosphorylate LATS1/2 at their 
hydrophobic motifs and result in LATS1/2 activation (Meng et al., 2015). Deletion of 
MST1/2 and MAP4Ks is required to abolish YAP phosphorylation in response to LATS-
activating signals, such as contact inhibition, energy stress, serum deprivation, and F-actin 
disassembly (Meng et al., 2015). Moreover, phosphorylation of YAP and TAZ leads to 
their binding in 14-3-3, causing YAP/TAZ cytoplasmic sequestration (Zhao et al., 2007). 
Furthermore, LATS-induced phosphorylation triggers subsequent phosphorylation of 
44 
 
YAP/TAZ by casein kinase 1d/e and recruitment of the E3 Ubiquitin ligase SCF complex 
subunit SKP1/ASK1 family protein (SCF E3 ubiquitin ligase), leading to eventual 
YAP/TAZ ubiquitination and degradation (Liu et al., 2010; Zhao et al., 2010a). 
Furthermore, YAP protein can also be degraded by autophagy (Liang et al., 2014). 
In this scenario, another important key player of the complex cascade downstream 
Hippo, is Neurofibromin 2 (NF2)/Merlin. This oncosuppressor protein directly interacts 
with LATS1/2 and facilitates their phosphorylation by the MST1/2-SAV1 complex 
(Yin et al., 2013). Subsequently, LATS1/2 auto-phosphorylates (Chan et al., 2005) and 
in turn inactivate YAP and TAZ (Zhao et al., 2007). Activated NF2 may play important 
roles in SCs development (detailed below). 
Mouse models with deletion of MST1/2, SAV1, MOB1A/B, Nf2, or LATS1/2 or YAP 
overexpression exhibit upregulation of TEAD, increased expansion of progenitor cells 
and tissue overgrowth (Chen and Harris, 2016), supporting their functional roles in the 
Hippo signaling pathway. 
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Figure 10 Models of the Hippo pathway in Drosophila and mammals. In mammals, functional role of Fat and Ex 
homologs are not clear. nevertheless, Merlin may still activate the Hippo pathway (Yokoyama et al., 2008). Ras 
associated family member (RASSF), a subgroup of Ras effector proteins, may also activate Mst1/2 (Oh et al. 2006). 
Relationships between Hpo, Sav, Wts, and Mats are conserved in mammalian Mst1/2, Sav1 (Sav homolog), Lats1/2 
(Wts homolog), and Mob (Mats homolog). Lats1/2 phosphorylates YAP on five conserved HXRXXS motifs (four on 
TAZ) (Zhao et al., 2007). Dependent on cell type and context, there may exist another YAP kinase in response to 
Mst1/2 and another Lats1/2 kinase (Zhou et al., 2009). S127 (S89 in TAZ) phosphorylation-dependent 14–3–3 
binding and cytoplasmic retention are conserved in YAP/TAZ (Zhao et al., 2007). YAP is also inhibited by S381 
phosphorylation, which primes serine-threonine kinase CK1d/e phosphorylation of S384, and S387 finally leads to 
mediated ubiquitination and degradation (Zhao et al., 2010a). Sd homologs, major YAP target transcription factors. 
They mediate expression of connective tissue growth factor (CTGF), GLI-Kruppel family member (Gli2), and many 
other target genes (Zhao et al., 2008). Amphiregulin (AREG) is induced by YAP through an unidentified transcription 
factor (Zhang et al., 2009). YAP and TAZ also bind Smad1 and Smad2/3 to activate expression of TGF-b and BMP 
target genes, respectively, to maintain stem cell pluripotency (Gao et al., 2009).  
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Hippo pathway in SCs 
In the PNS, it was shown that YAP and TAZ activate the mTORC1 pathway to promote 
myelination (Kim et al., 2005), and interact with TEAD1 to control Pmp22 gene 
expression (Lopez-Anido et al., 2016). Moreover, in the cytosol of SCs, YAP and TAZ 
are phosphorylated and inhibited by LATS1/2 kinases. YAP and TAZ are fundamental 
for immature SCs development and myelin gene regulation. These transcriptional 
regulators are required for SC proliferation and axonal sorting. SCs require YAP and 
TAZ to enter S-phase and, without them, fail to generate SCs axonal sorting (Grove et 
al., 2017). Moreover, they are implicated in the differentiation process, regulating the 
transcription of Krox-20 (Grove et al., 2017), which is a key modulator of the 
myelination in SCs (Topilko et al., 1994). The capacity of YAP and TAZ to initiate and 
maintain SC myelination may depend by different pathways, such as the positive 
regulation of zinc-finger E-box binding homeobox 2 (ZEB2) transcription factor, that 
promotes SC differentiation by inhibiting some differentiation repressors (Quintes et 
al., 2016). 
Furthermore, it is important to underlie that YAP and TAZ are downstream of other 
regulators of myelination, including NRG-1 type III, integrin a6b, adhesion g protein 
coupled receptor G6 (GPR126) and wingless (WNT) (Quintes et al., 2016; Grove et al., 
2017). 
NF2 gene 
NF2 gene encodes the 4.1 ezrin, radixin, moesin domain (FERM domain) protein 
Merlin, regulated by the intracellular adhesion and the attachment to the extracellular 
matrix (Rouleau et al., 1993; Okada et al., 2005). NF2 gene maps to the long arm of 
chromosome 22 and encodes two Merlin isoforms (Figure 11A). The long, Merlin 
47 
 
isoform 1 (Merlin-1 or Merlin), has an extended carboxy-terminal tail that is encoded 
by exon 17. Merlin isoform 2 (Merlin-2), indeed, contains the alternatively spliced exon 
16 which ends in a stop codon, encoding 11 residues following amino acid 579 (Bianchi 
et al., 1994). Notably, Merlin-2 does not possess carboxy-terminal residues, required 
for intramolecular binding between the amino-terminal FERM domain and the carboxy-
terminal tail, probably determining the constitutively open conformation (Sherman et 
al., 1997; Gonzalez-Agosti et al., 1999). Several recent studies have found that Merlin-2 
has a function in cell proliferation, working downstream mitogenic signaling in the same 
entity as Merlin-1 (Lallemand et al., 2009; Sher et al., 2012; Cooper and Giancotti, 2014)  
General concepts 
Merlin is an oncosuppressor protein with an high sequence homology to the ERM 
family of cytoskeletal linker proteins. In fact, in the cell membrane, Merlin suppresses 
mitogenic signaling and mediates contact inhibition and tumor suppression 
(McClatchey and Fehon, 2009). Merlin has 64% sequence similarity with family 
members of the conserved FERM domain at the N terminus. The FERM domain is 
followed by an a-helical domain and a C-terminal. In contrast to the other ERM 
proteins, merlin lacks the actin-binding site located in the C-terminal domain, it has a 
unique actin binding motif in the N-terminal domain (Xu and Gutmann, 1998). FERM 
proteins link the actin cytoskeleton to plasma membrane receptors (Trofatter et al., 
1993). The dephosphorylated active form of Merlin suppresses RAC-PAK signalling 
(Shaw et al., 2001; Kaempchen et al., 2003; Okada et al., 2005). Moreover, 
dephosphorylated merlin restrains activation of mTORC1, independently of AKT 
(James et al., 2009; López-Lago et al., 2009) inhibits PI3K-AKT and FAK-SRC 
signalling (Rong et al., 2004; Poulikakos et al., 2006) and negatively regulates the 
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EGFR-RAS-ERK pathway (Jin et al., 2006; Ammoun et al., 2008). Moreover, Merlin 
activates the Hippo tumor suppressor signaling pathway, abolishing the transcriptional 
coactivators YAP/TAZ. This evidenced a conserved role for Merlin in the control of 
organ size, stem cell behavior, and cell proliferation (Zhao et al., 2007; Zhang et al., 
2010).  
Recent studies shed light also on the conformational changes that regulate Merlin 
intramolecular associations and downstream signaling. Merlin indeed, has a bimodal 
function (Figure 11B). Post-translational modifications lead to the conversion of Merlin 
into the inactive state, with growth inhibitory properties. Dephosphorylated and open 
state Merlin, indeed, is active in the contact inhibition of growth and tumor suppression 
(Sher et al., 2012; Cooper and Giancotti, 2014). 
Merlin regulates the tight junction protein angiomotin, thus inhibiting RAC signalling 
(Yi et al., 2011). Nuclear localization of Merlin inhibits the CRL4DCAF1E3 ubiquitin 
ligase then suppressing oncogenic expression (Li et al., 2010).  
Merlin, like ERM protein, is also active as scaffold protein at the plasma membrane, 
where it is phosphorylated at Ser518, promoting receptor mediated events associated 
with cell proliferation and survival. Ser518 is substrate of p-21 activated kinase (PAK) 
and PKA, inactivating Nf2 tumor suppressor activity (Shaw et al., 2001; Alfthan et al., 
2004). Phosphorylated Merlin adopts an open and active configuration at the plasma 
membrane. Conversely, dephosphorylation at S518, mediates the transition to a closed 
conformation, inactivating its scaffold function and contemporarily activating its tumor 
suppressor function. The closed head-to-tail conformation of the active tumor-
suppressor was believed to be incapable of interaction with the of growth factor 
receptors (Curto et al., 2007; Yogesha et al., 2011). 
49 
 
 
 
Figure 11 Merlin structure. (A) Merlin contains three conserved protein-protein interaction domains: a FERM 
domain in its N-terminus and a C-terminal domain (CTD) separated by a coiled-coil (α-helical) region (CCR). 
Crystallography showed that the merlin FERM domain contains three subdomains, which exhibits a cloverleaf 
architecture. Merlin FERM has a unique `Blue Box' (BB, residues 177-183) compared with other ERM proteins. (B) 
Merlin can adopt two conformations: a `closed' active and `open' inactive form. Merlin can switch from these two 
conformations as a result of phosphorylation, lipid binding, protein interactions or NF2 mutations. (Sun et al., 2002) 
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NF2 gene role in SCs 
Merlin is present also in the PNS. Given that merlin is part of the ERM complex, it was 
expected to be located in the node of Ranvier. However, Merlin has not been detected 
in SCs microvilli, but was found at the level of paranodes in sciatic nerves. Paranodin, 
also known as contactin associated protein (Caspr), is a neuronal protein that is highly 
expressed in paranodal axoglial junctions. Merlin binds to paranodin through its FERM 
domain and, at least in CNS, it forms a complex with b1 integrin and paranodin 
(Denisenko-Nehrbass et al., 2003). Some factors link, directly or indirectly, Merlin to 
the cytoskeleton, even in the PNS. Indeed, merlin interacts with different proteins 
including spectrin (Scoles et al., 1998), the solute carrier family 9, sodium/hydrogen 
exchanger, member 3 regulator 1 (NHERF) (Murthy et al., 1998; Gonzalez-Agosti et al., 
1999), the schwannomin interacting protein 1 (SCHIP1) (Goutebroze et al., 2000), the 
hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) (Scoles et al., 2000), 
syntenin, CD44 (Grönholm et al., 1999; Morrison et al., 2001), b1 integrin (Obremski et 
al., 1998), F-actin (James et al., 2001) and paxillin (Fernandez-Valle et al., 2002). 
Importantly, Merlin is a key factor for the pathogenesis of neurofibromatosis type 2 
(NF2). Schwannomas are SC-derived benign tumors that occur sporadically and/or in 
patients with NF2 (MacCollin et al., 2003). Sporadic schwannomas and NF2 tumors 
show a loss of Merlin, but not of ERM proteins (Stemmer-Rachamimov et al., 1997). 
However, is still unclear how the loss of Merlin may impact on tumor pathogenesis, 
whereas a tumor suppressor function of Merlin, has been hypothezise. Studies on Nf2 
knock out mouse models show that these animals developed schwannoma and 
meningiomas, which are the hallmarks of the human disease (McClatchey et al., 1998; 
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Giovannini et al., 1999). Moreover, conditional loss of merlin in SCs lead to hyperplasia 
and tumor development in mice (Giovannini et al., 2000; Kalamarides et al., 2002).  
Merlin-deficient schwannoma cells show cytoskeletal reorganization when compared 
with normal human SCs, indicating an important and evident defect of the actin 
cytoskeleton (Pelton et al., 1998; Bashour et al., 2002). Cytoskeletal changes were 
recovered after acute expression of Merlin in these cells, showing a direct role for 
Merlin in actin reorganization (Bashour et al., 2002). 
Neurofibromatosis and Schwannomatosis 
Neurofibromatosis is an heterogeneous group of hereditary syndromes that generate 
tumors of the CNS and PNS. The most common form is neurofibromatosis type 1 (NF1 
96%), followed by NF2, (3%), and a lesser common form of schwannomatosis. 
Neurofibromatosis incidence is almost the same among genders and different ethnic 
groups. (Kresak and Walsh, 2016). 
NF2 has an inherited autosomal dominant pattern with an incidence of 1 in 25,000, 
prevalence of 1 in 60,000, and a penetrance of approximately 0.95 (Laulajainen et al., 
2008). The disease is caused by a mutation in the NF2 gene. More than a half of the 
cases, are caused by sporadic gene mutations in patient with no family history of the 
disease (Kresak and Walsh, 2016), or a loss of NF2 gene mutation with an high 
frequency of somatic mosaicism (Petrilli and Fernández-Valle, 2016). Notably, NF2 
mutations are present in several malignant cancers including mesotheliomas, colorectal, 
hepatic, breast, prostate, clear cell renal cell carcinoma and melanomas.  
Recent publications highlights the importance of SCs-axon interactions in preventing 
schwannoma formation and the contribution of axonal expression of Merlin isoform 2 
(Schulz et al., 2013, 2014a; b). NF2-associated schwannomas exhibit NF2 inactivation 
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which manifests in a failed production of Merlin protein (Sainz et al., 1994). Indeed, 
Merlin protein expression has found to be highly reduced or completely absent in 11 of 
14 sporadic schwannomas, 16 of 19 sporadic meningiomas and 3 of 8 sporadic 
ependymomas (Gutmann et al., 1997). Mutational NF2 inactivation and loss of 
heterozygosity (LOH) is the cause of the most NF2-associated schwannomas and 
sporadic schwannomas. Transcriptional inactivation causes 15.3% of NF2-associated 
schwannomas and 19.3% of sporadic schwannomas (Gonzalez-Gomez et al., 2003). 
Moreover, one study reported that methylation of three CpG sites, in the NF2 promoter 
elements was found in ~60% of vestibular schwannomas and correlated with the 
decreased promoter activity and mRNA expression (Kino et al., 2001). On the other 
hand, another study of 35 sporadic vestibular schwannomas reported that in 65% of 
tumors the NF2 promoter was unmethylated and in the remaining 35% the results were 
inconclusive (Koutsimpelas et al., 2012). At the same time, 50-60% of sporadic 
meningiomas contain NF2 somatic mutations and epigenetic inactivation (Lomas et al., 
2005; Riemenschneider et al., 2006). Another study, considered 88 sporadic 
meningiomas, 49% exhibited allelic loss of chromosome 22, 24% had NF2 somatic 
mutations and 26% had aberrant NF2 promoter methylation, whereas in 17% of 
meningiomas, epigenetic NF2 inactivation was the only cause of NF2 deficiency. 
Similarly, less then 10% of sporadic ependymomas have NF2 promoter methylation. In 
some schwannomas and meningiomas without genetic or epigenetic NF2 inactivation, 
merlin inactivation was caused by µ-calpain, constitutive activation that mediated 
merlin proteolytic cleavage/degradation (Kimura et al., 1998). Finally, a recent study of 
meningiomas in 73 patients found a high incidence of telomerase reverse transcriptase 
(TERT) promotes mutations in there meningiomas undergoing malignant 
53 
 
transformation. However, TERT mutations were found in benign tumors. This suggests 
that TERT, independently of NF2, is a biomarker of malignant transformation of 
meningioma (Goutagny et al., 2014).  
Considering that Nf2 heterozygous mice are prone to develop cancers, primarily 
osteosarcomas, fibrosarcomas and hepatocellular carcinomas, it was assumed that 
NF2 patients commonly develop other malignant cancers (McClatchey et al., 1998). 
The incidence of NF2 mutations in common human cancers is low. The transformation 
of schwannomas into malignant peripheral nerve tumors or development of other 
common cancers is very rare. Despite the fact that NF2 mutations have been detected 
in multiple human tumor types, mutational analysis of 315 human carcinoma samples 
found a low prevalence of NF2 mutations, in fact they were found in just 2.2% of 
hepatocellular, acute myelogenous leukemia and squamous cell lung carcinomas 
(Bianchi et al., 1994; Yoo et al., 2012).  
In conclusion, despite Merlin is ubiquitary expressed in normal tissues, loss of merlin in 
humans mostly leads to SC-derived tumors, suggesting that a specific molecular contest 
and the microenvironment are strongly required for this oncogenic transformation.  
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The role of microRNAs in myelination 
General concepts 
MicroRNAs (miRNAs) are small non-coding RNA molecules containing about 22 
nucleotides, which can be found in plants, animals and some viruses. They are encoded 
by eukaryotic nuclear DNA in plants and animals and by viral DNA in viruses. MiRNAs 
function in transcriptional and post-transcriptional regulation of gene expression (Chen 
and Rajewsky, 2007). MiRNA function via base-pairing with complementary 
sequences within mRNA molecules. This determine the silencing of mRNAs, which 
cannot be translated by ribosomes. Animal miRNAs recognize their target mRNAs by 
small sequence of 6-8 nucleotides (the seed region) at the 5’ end of the miRNA (Lewis 
et al., 2003, 2005). Importantly, miRNAs may target a large and different amount of 
mRNA as well as mRNA may be targeted by multiple miRNAs.  
The human genome may encode over 1000 miRNAs (Bentwich et al., 2005) which 
target about the 60% of mammalian genes. Mammalian cells use miRNA for acute and 
rapid regulation of gene expression, thus inducing transcriptional (Morris et al., 2004), 
or post-transcriptional gene silencing (Ambros, 2004; Bartel, 2004) as well as 
epigenetic modifications (Castanotto et al., 2005). MiRNAs target multiple mRNAs 
leading to post-translational repression or also to mRNA degradation (Hannon et al., 
2006). The enzyme RNase III Dicer, processes miRNAs into segment about 22 
nucleotide longer, this long mature RNA duplexes (Kim et al., 2009) are loaded into the 
RNA-induced silencing complex (RISC complex), which contains Argonaute (AGO) 
proteins (Tabara et al., 1999; Martinez et al., 2002) (Figure 12).  
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Figure 12 Synthesis and mechanism of miRNAs. After synthesis of the primary RNA transcript (pri-miRNA), the 
molecule is processed by the endonucleases Pasha and Drosha to yield the pre-miRNA. Secondly, pre-miRNA is 
export to the cytoplasm and the mature miRNA is generated by a cleavage step mediated by Dicer. The mature 
miRNA is then loaded onto the RNA-induced silencing complex (RISC). This complex can affect the degradation or 
translational repression of mRNAs complementary sequences to the miRNA. (Melman et al., 2014). 
In general, miRNAs affect the overall protein expression state of the cell, leading to a 
global effect on cellular health and differentiation state. Recently, several papers have 
identified fundamental roles for miRNAs in controlling the development, 
differentiation, and health of myelinating cells of the mammalian nervous system 
(Dugas and Notterpek, 2011). 
To study the role of miRNAs in biological processes, a typical approach is the knock 
down of Dicer1 (Bartel, 2004), but the animal fail to survive around embryonic day 7.5 
(E7.5), preventing further longitudinal studies (Bernstein et al., 2003). Therefore, to 
study the requirement of mature miRNAs in postnatal processes, Cre-mediated 
recombination is functional to obtain the disruption of DICER1, specifically in cells of 
interest. 
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MiRNAs in the nervous system 
Mature miRNA production is necessary, not only for the generation of compact CNS 
myelin during development but, also to maintain healthy and functional myelin sheaths 
in adult nerves (Dugas and Notterpek, 2011) in the mammalian CNS, miRNAs are 
important in all stages of OL generation and myelination.  
MiRNAs are able to influences OL biology, and CNS myelination, through the 
activation of different mechanism: the suppression of OL-precursors cell (OPCs) 
expressed genes, the promotion of OPCs expansion, the suppression of inappropriate 
non-OL gene expression in OPCs and OLs and the suppression of genes transiently 
required during myelin sheath formation (Dugas and Notterpek, 2011). In uncommitted 
neural precursors the knock out of Dicer1 (by driving Cre expression from the Nestin 
promoter) leads to a reduction in OL lineage, both mature OLs and immature OPCs 
(Kawase-Koga et al., 2009). On the contrary, the disruption of DICER1 function in 
specific OPCs and OLs (by expressing Cre from either the Olig1 or Olig2 promoter) 
does note reduce OPC number in vivo (Dugas et al., 2010a; Zhao et al., 2010b). 
However, OPCs in which Dicer1 is silenced do not differentiate normally, as OL  
differentiation and myelin formation are significantly altered in Olig1-Cre, Olig2-Cre, 
and 2’,3’-cyclic nucleotide 3’ phosphodiesterase (CNP)-Cre Dicer1fl/fl mice. OPCs 
purified from these animals fail to differentiate normally in vitro (Dugas and Notterpek, 
2011). Furthermore, the specific disruption of DICER1 in fully mature OLs, by driving 
tamoxifen-inducible Cre expression from a myelin proteolipid protein (PLP) promoter, 
leads to the degradation of CNS myelin (Shin et al., 2009).  
In accordance with a previous work from Lau and colleagues in 2008, that characterized 
miRNA expression in OLs, in 2010, two groups independently, identified miR-338 and 
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miR-219, that are highly induced in differentiating OLs (Dugas et al., 2010b; Zhao et 
al., 2010b). The expression of miR-219 is evident in mature OLs, in brain and spinal 
cord, while miR-338 is less expressed in the brain, as strong expression of miR-338 is 
only detected in the spinal cord (Dugas et al., 2010b; Zhao et al., 2010b). In addition, 
other two miRNA were identified as inducer of OL maturation and differentiation, miR-
23a and miR-23b, (Lin and Fu; Lau et al., 2008), which reduce the expression of a gene 
inhibiting normal OL maturation. Albeit miR-219 promotes all stages of OL 
differentiation, miR-138, specifically promotes the early stages (indicated by 
expression of myelin proteins CNP and MBP) of OL differentiation and simultaneously 
suppressed the later stages identified by the myelin oligodendrocyte glycoprotein 
(MOG) (Dugas et al., 2010b).  
On the contrary, another class of miRNAs seem to block OL differentiation. In fact, 
members of the miR-17-92 cluster were expressed at high levels in both OPCs and 
OLs, whereas were necessary to enhance OPC proliferation in vivo and in vitro (Budde 
et al., 2010). In particular, Budde and colleagues found that a member of this cluster, 
miR-19b, increases OPC proliferation in vitro. In general, all these findings 
demonstrated that different miRNAs can assume several and opposite roles in the 
process of OL differentiation. 
MiRNAs in the PNS 
Similarly to OLs in the CNS, SC differentiation and peripheral nerve myelination 
depends on communication between axons and glial cells. The switch in phenotype 
from a proliferating to a differentiated SCs involves transcriptional and translational 
gene regulatory mechanisms, including gene repression via miRNAs.  
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Several studies demonstrated that miRNAs are fundamental candidate for the regulation 
of peripheral nerve myelination. While some miRNAs are induced during 
differentiation (miR-219, -338, -138), several miRNAs present high levels in pre-
myelinating SCs but then decrease during myelination (Svaren, 2014). In SCs, at least 
some of these miRNAs rebound after peripheral nerve injury (Viader et al., 2011b; 
Adilakshmi et al., 2012). In mouse models where Dicer was specifically ablated in SCs 
(using P0-Cre), the SCs underwent the normal radial sorting process, although delayed 
(Bremer et al., 2010b; Pereira et al., 2010; Yun et al., 2010). Nevertheless, SCs lacking 
Dicer produce no myelin and instead continue to proliferate. The knock out animals 
show a decrease in myelin gene expression and lower levels of the EGR2/KROX20 
transcription factor, important factors implicated in the progression of myelination. This 
animals showed an induction of immature (or non-myelinating) SCs markers, such as 
P75/NGFR, SRY-Box2 (SOX2), NOTCH1, and C-JUN in the absence of DICER. Some 
studies studies show that, the use of Dhh-Cre failed to show any proliferation changes 
at P4 (Pereira et al., 2010), but in a separate study with the same Cre-driver, the increase 
in proliferation was seen at P22, when there are only few dividing cells in control nerve 
(Bremer et al., 2010a). Using the P0 – Cre driver, Dicer ablation induces an increase in 
proliferation, that was observed before the P7, with further increase at P14 (Yun et al., 
2010). Moreover, POU domain, class 3, transcription factor 1 (OCT6/POU3F1) and 
POU domain, class 3, transcription factor 2 (BRN2/POU3F2), pro-myelinating SCs 
markers, show a reduction in mRNAs levels at P4 (Bremer et al., 2010a), in accordance 
to the light reduction of OCT6/POU3F1 protein at P5 show in the study of Pereira and 
colleagues. Furthermore, many SCs arrest their cycle at a pro-myelinating stage after 
P20. Accordingly, immunohistochemistry performed in the P0-Cre study revealed an 
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increased number of OCT6/POU3F1 positive SCs at P22 (Yun et al., 2010). In the 
absence of DICER, another important parameters that is studied is the NRG/AKT 
pathways (Nave and Salzer, 2006) in early postnatal time points (Bremer et al., 2010a; 
Pereira et al., 2010). In mouse models, with a peripheral nerve-specific deletion of Dicer 
enzyme, SCs “arrest” the production of myelin and instead continue to proliferate and 
express markers of immature SCs such as SOX2 and C-JUN (Bremer et al., 2010a; 
Pereira et al., 2010; Yun et al., 2010). Conversely, the study of Pereira and colleagues 
demonstrated a persistent development of myelin profiles despite the lack of DICER, 
which was enhanced in dorsal roots compared to ventral roots and sciatic nerve (Pereira 
et al., 2010), suggesting that DICER is not required for myelin initiation. Interestingly, 
by using an inducible Plp-Cre to knock down Dicer in mature mice, it was shown that 
the loss of DICER had a small effect on myelin maintenance and on the early stages of 
nerve injury. Also the recovery of myelination after nerve crush injury was imperfect 
(Viader et al., 2011a). These data indicates that DICER is not required for the 
demyelination after nerve injury, but rather for re-myelination process. Studies of Dicer 
knock out mice indicated that miRNA expression is required non only for the control of 
differentiation status of the cell, but also for the cell cycle exit, thus for the regulation 
of proliferation (He et al.; Dugas and Notterpek, 2011). 
Microarray analysis identified different groups of miRNAs that are developmentally 
regulated during maturation of SCs (Bremer et al., 2010a; Pereira et al., 2010; Yun et 
al., 2010; Gokey et al., 2012). In particular, analysis of miRNAs in SCs showed that 
miR-138 is induced during myelination. This was confirmed by the 3’ UTR luciferase 
assays, showing that miR-138 could reduce the expression of SOX2, C-JUN and cyclin 
D1 (Yun et al., 2010), key factors that are downregulated during peripheral nerve 
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myelination. PMP22 is a candidate for post-transcriptional regulation by miRNAs, 
because its product is a protein whose levels are critical for normal SC function. In fact, 
over- and under-expression of PMP22 have been associated with hereditary 
demyelinating neuropathies in humans (Chance, 2004). Interestingly, by using an 
inducible Plp-Cre to knock down DICER in mature mice, it was shown that the loss of 
Dicer had a small effect on myelin maintenance and on the early stages of nerve injury. 
Also the recovery of myelination after nerve crush injury was imperfect (Viader et al., 
2011a). These data indicates that DICER is not required for the demyelination after 
nerve injury, but rather for re-myelination process. 
Recently, several studies applied the microarray analysis to the study of miRNA 
profiling in peripheral nerve after a nerve lesion (Viader et al., 2011a; Adilakshmi et 
al., 2012; Yu et al., 2012). It was shown an injury-induced decline in miR-338 and 
miR-138 in nerve. Moreover, the half of miRNAs expressed in SCs resulted regulated 
by the injury.  
Recent findings from two different studies show that, in proximal nerve following rat 
sciatic nerve transection, there is an increase expression of miR-sc8, which induces the 
inhibition of cell proliferation and migration of SCs. Viceversa, the silencing of miR-
sc8 show the enhance of cell proliferation and migration. The EGF-R was identified as 
the target gene of miR-sc8, thus exerting negative regulation of EGF-R by translational 
suppression (Gu et al., 2015). An increased and decreased expression of miR-sc3 
promoted and reduced the proliferation and migration of primary SCs, respectively.  
Indeed, some specific miRNAs pathways mediate cell cycle exit, such as the miR-34a 
that targets cyclin D1 and Notch1 (Bremer et al., 2010a; Viader et al., 2011a). Notch1 
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antagonize the myelination process and promote proliferation, moreover, its expression 
is downregulated when SCs terminally differentiate (Woodhoo et al., 2009).  
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Peripheral nervous system disorders 
PNS disorders are diseases of the peripheral nerves which includes diseases of the nerve 
roots, ganglia, plexi, autonomic nerves, sensory nerves and motor nerves (described in 
the PubMed database, MeSH, Ref n° 68010523). Among these the peripheral hereditary 
motor and sensory neuropathies represent the main subgroups. 
Peripheral neuropathies (PN) 
PN is a term generally referring to a damage or disease affecting nerves, which may 
impair motor and sensory function depending on the type of nerve affected. PN is a very 
heterogeneous class of disease of different origin. Indeed, common causes are systemic 
diseases (such as diabetes), medications (like chemotherapy, metronidazole and 
fluoroquinolone), antibiotics (ciprofloxacin, levaquin etc.), vitamin deficiency (vitamin 
B12), traumatic injury (including ischemia or radiation therapy) excessive alcohol 
consumption, immune system disease, coeliac disease or viral infection. PN can be 
idiopathic or hereditary (Hughes, 2002; Torpy et al., 2008). Other most common forms 
of PN are hereditary PN (HPN), including motor and sensory neuropathies (HMSN), 
motor neuropathies (HMN) and sensory neuropathies (HSN). The most frequent is the 
Charcot-Marie-Tooth (CMT) disease, which may be considered a group of 
heterogeneous disorders, classified on the basis of their clinical, neurophysiological, 
genetic and pathological features. CMT is divided into two main subtypes, CMT1 and 
CMT2 distinguished on the basis of electrophysiological and biopsy classification 
(Dyck P and Lambert EH, 1968; Harding and Thomas, 1980a). The CMT1A is the most 
common form and its molecular cause is ascribed to the duplication of the chromosome 
17, containing the PMP22 gene, although more than 75 genes responsible for the onset 
of the pathology have been identified (Table 1). These disorders are inherited as an 
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autosomal dominant trait, although autosomal recessive and X-linked forms may exist 
(Harding and Thomas, 1980b) (Table 1). However, the autosomal recessive inheritance 
may account for more than 30 to 50% of all forms (Dubourg et al., 2006).  
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Type                             Gene      Onset Phenotype 
 
 
 
 
  Table 1 Classification of HMSN or CMT diseases. Adapted from: Tazir et al, 2014 – J Neurol Sci. 
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CMT is slowly progressive and usually have an onset in the second decade of life, 
depending on genetic abnormalities. The classical phenotype includes limping, 
moderate distal sensory deficit, and distal lower amyotrophy giving an aspect of “jambs 
de coq”. Most of patients do not complain significant sensory troubles, although 20-
30% of CMT1 patients manifest pain, often musculoskeletal and rarely neuropathic. 
Other characteristics are decreased or absent deep tendon reflexes, balance impairment 
(because of proprioceptive loss) and skeletal deformities. The pes cavus and 
hammertoes, complete the typical CMT phenotype. 
The electrophysiological study is the first approach to distinguish myelinopathies from 
neuronopathies or axonopathies. The severity of the neuropathy can be evaluated also 
by a CMT neuropathy score, a nine-time clinical examination that measures sensory 
symptoms, motor symptoms, arm and leg strength and nerve conduction velocities. 
The therapeutic approach is similar to other chronic neuromuscular disorder and is 
based on physical therapy and associated rehabilitative measures. Moderate exercise 
and stretching to avoid osteo-articular complications are generally tolerated. Patients 
with limb and vertebral deformities often need corrective orthopedic surgeries.  
Unfortunately, pharmacological approaches are not sufficient and the prognosis is often 
poor, since most of the drugs tested are not reliable. For instance, ascorbic acid, that 
was promising in phase I studies (Passage et al., 2004), did not improve the clinical 
outcomes in humans. Other drugs are used with an empirical approach. Recently, a 
phase II clinical trial involving patients with CMT1A treated for one year with 
PXT3003, a low dose combination of the three already approved drugs, baclofen, 
naltrexone and D-sorbitol, showed promising results. The drugs are safely and tolerable. 
However, the analysis of the outcomes is still in progress (Attarian et al., 2014). 
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Neurofibromatosis 
NF1, NF2 and schwannomatosis are a spectrum of tumor syndromes caused by a 
mutation in different tumor suppressor genes (Blakeley and Plotkin, 2016). Mutation of 
these genes induce dysregulation of pathways responsible for cell division and correct 
proliferation, resulting in vulnerability and additional genetic alterations that evolve in 
cancer formation. Nevertheless, in patients with NF1, NF2 or schwannomatosis, the 
tumor are histologically benign (with a low incidence of malignancy), involving the 
CNS and the PNS. These tumors lead to the loss of nervous system function and in rare 
cases mortality. 
NF1 is a rare pathology, with an incidence of 1 in 2500-3000 individuals, however is 
the main autosomal dominant disorder of the NS and one of the most common gene-
inherited conditions (Vogel et al., 1999). NF1 disease can impact every system, but 
the skin, CNS and PNS are commonly affected. Specifically, the skin lesions include 
cafè au lait spots, as well as coetaneous and subcutaneous neurofibromas. Plexiform 
neurofibroma (pNF), is a multicellular tumor representing the most common tumor in 
NF1. It is composed of variety of cell types, including neuronal axons, SCs, 
fibroblasts, mast cells, macrophages, perineurial cells and extracellular matrix 
(Laycock-van Spyk et al., 2011). 
NF2 has an estimated incidence of 1 in 25000-33000 births (Wiszniewski). Like NF1, 
is associated with multiple tumors of the CNS and PNS. The characteristic tumors in 
the NF2 pathology are schwannomas, occurring in intracranial or extracranial 
peripheral nerves and meningiomas. The diagnostic criteria include the bilateral 
schwannomas of the superior vestibular branch of the eight cranial nerve known as 
vestibular schwannoma, (VS, or acoustic neuroma) (Kresak and Walsh, 2016). Namely, 
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VS is the main cause of morbidity in patients affected by NF2 disease. VSs can induce 
bilateral sensorineural hearing loss, tinnitus, balance difficulty and deafness, facial 
nerve weakness and possible brainstem compression (Agrup et al., 2007). In adulthood, 
a more generalized symptomatic severe polyneuropathy occurs in about 3–5% of 
patients, often associated with an "onion bulb" appearance on nerve biopsy (Evans et 
al., 1992), progressing to severe muscle wasting and even death. However, around 40% 
of patients show evidence of polyneuropathy (Sperfeld et al., 2002) and ophthalmic 
features, leading often to visual acuity reduction. 
 Nevertheless, 41% of patients have no bilateral VSs at the onset of the pathology, for 
this reason, a body of diagnostic criteria has been created for NF2. These characteristics 
include the widely recognized “Manchester criteria” as well as additional NIH criteria 
shown in table below (Table 2). 
Main criteria Additional criteria 
Bilateral vestibular schwannomas or Unilateral vestibular schwannoma plus any two of the following: 
meningioma, glioma, schwannoma, or juvenile posterior 
lenticular opacities or 
First-degree relative with neurofibromatosis type 2 plus 
1-unilateral vestibular schwannomas or 
2-any two of the following: meningioma, glioma, schwannoma, 
or juvenile posterior lenticular opacities 
At least two meningiomas plus 
1-unilateral vestibular schwannoma or 
2-any two of: glioma, neurofibroma, schwannoma, and cataract 
Table 2 Clinical diagnostic criteria for NF2. (Kresak and Walsh, 2016) 
The NIH criteria include patients with no family history who have multiple 
schwannomas and/or meningiomas, not yet developed. Patients who have asymmetric 
involvement are probably mosaic (Evans et al., 1999). At very young ages, less then 18 
years old, individuals presenting with an apparently isolated meningioma or vestibular 
schwannoma (Figure 13) (Plotkin et al., 2011) have respectively 20% and 10% 
likelihood of developing NF2. However, after 20 years of age this rate drops 
dramatically and the diagnosis becomes very difficult after 30 years of age (Plotkin et 
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al., 2011). The diagnostic method is: clinical and family history, cutaneous and 
ophtalmic examination, craniospinal magnetic resonance imaging (MRI), molecular 
analysis. 
 
 
Figure 13 An acoustic neuroma expands out of the internal auditory canal, displacing the cochlear, facial, and 
trigeminal nerves located in the cerebellopontine angle. Eventually, the tumor compresses the brainstem. 
https://www.mayfieldclinic.com/PE-Acoustic.htm 
Assessment of the frequency of NF2 in the population is possible whit clinical 
diagnostic criteria based on mutations in the NF2 gene (Evans et al., 1992; Rouleau et 
al., 1993; Trofatter et al., 1993). However, this is difficult because there are an high 
number of mosaicism (Evans et al., 1998). 
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Standard mutation techniques detected 35-66% of pathogenic mutations (MacCollin et 
al., 2003; Baser et al., 2004). Detection rates are much higher for no-mosaic NF2, 
mosaics require testing of two tumors or sensitive Next Generation sequencing. The 
majority of these mutations were truncating mutations, leading to the formation of 
smaller and non-functional protein. Missense mutations of NF2 gene, large deletions 
(which result in no protein product) cause mild phenotypes; studies conducted on 
different families confirmed these findings (Baser et al., 2004). The C > T transitions 
leading to a nonsense mutation are the most common mutations in the NF2 gene 
(Ahronowitz et al., 2007). Phenotype is more variable in patients with alternative 
splicing mutations that manifest a mild disease (Baser et al., 2004, 2005). In particular, 
the mild cases bear a mosaicism, in which only a proportion of cells contain the mutated 
NF2 gene, and this proportion depends on how early in development the mutation 
occurs. In fact, recent evidence suggests that up to 20-30% of NF2 cases without a 
family history are mosaic, that bear the mutation in a small population of lymphocytes, 
undetectable from blood samples (Kluwe et al., 2003; Evans et al., 2007). The 
mosaicism present mutation which can be detected by analyzing tumor material from 
an affected individual. If an identical mutation is found in two tumors from that 
individual, their offspring can be tested for the presence of the mutation. However, if 
an offspring has inherited the mutation, they will have a typical phenotype and usually 
be more severely affected than their parent, since the offspring will carry the mutation 
in all of their cells (Evans et al., 2007). 
The management of NF2 is the surgical removal of symptomatic cranial and spinal 
tumors, although the surgical approach is generally complicate. It is important to 
balance the use of microsurgery and radiation treatment, that can be the therapeutic 
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option in patients who exibit aggressive tumors, poor surgical risks, or refuse surgery. 
This therapeutic choice may be carried on even if the tumor is larger than the size 
criterion for treatment (Rowe et al., 2002).  
The facial weakness, after microsurgery, compromise the health of the eye, resulting in a 
loss of the protective blink reflex, and tear production. Moreover, if the trigeminal nerve 
is involved, the eye becomes exceptionally vulnerable to corneal ulceration and blindness.  
Beside microsurgery and the radiation therapy, the majority of NF2 patients become 
completely deaf, especially because the tumors in these patients are more difficult to 
treat than those in patients with sporadic unilateral VS. Teams experienced in the 
positioning of brainstem implants can offer partial auditory rehabilitation to those who 
are deaf, although results are minor compared to cochlear implants. Although the 
cochlear nerve may be left intact after surgery, its blood supply may be altered. 
Nonetheless, few patients can be rehabilitated successfully with a cochlear implant 
(Rowe et al., 2002).  
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Mechanical cues 
Mechanobiology is a particular field of sciences that study the effect of physical forces, 
like stretching and compression on living systems (Halder and Bhattacharyya, 2012). 
Cells are able to translate a physical stimulus into biochemical signals, by activating 
mechanotransduction systems. By this mechanism cells control different processes such 
as cell behavior, growth, differentiation and also tumor progression (Dupont et al., 
2011). For instance, during the embryonic development, the physical features of the 
extracellular matrix and mechanical forces are integral to morphogenetic processes, 
defining tissue organization and architecture (Mammoto and Ingber, 2010; Dupont et 
al., 2011). The physical stimuli that are of interest in mechanobiology include 
mechanical challenges and radiation exposition. 
The study of mechanical stimuli that guide the development of myelinating glial cells 
was only recently addressed (Jagielska et al., 2012; Lourenço and Grãos, 2016). In the 
last year, studies on electromagnetic field (EMF) indicated that the environment may 
affect SCs development (Lacy-Hulbert et al., 1998). Although the nature of the forces 
that affect the SCs differentiation in vivo remains non fully understood, as well as their 
potential involvement in pathogenic alterations and tumorigenesis, SCs were shown to 
be mechanosensitive (Poitelon et al., 2017).  
Among different intracellular mechanisms, YAP and TAZ are generally activated by 
mechanical stimuli, thus regulating SC proliferation and the transcription of genes 
encoding for basal lamina receptors (Poitelon et al., 2016). 
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EMF stimulation 
Stimulation with EMF at low frequency (20 Hz) has been used for long time in therapy, 
for regenerative medicine, particularly for the promotion of nerve regeneration (Gürler 
et al., 2014). Brief electrical stimulation is effective in accelerating axon outgrowth 
across injury sites (Al-Majed et al., 2000b; Brushart et al., 2002). The electrical 
stimulation is also able to increase neurotrophic factors expression and, in turn, growth-
associated genes (Al-Majed et al., 2000a).  
Moreover, magnetotherapy uses magnetic devices includes magnetic bracelets, insoles, 
wrist and knee bands, back and neck braces, and even pillows and mattresses (Finegold 
and Flamm, 2006). 
A brief post-surgical stimulation with electrical input is a cooperating therapy for nerve 
regeneration (Chan et al., 2016). Its potential for clinical translation has been 
demonstrated in two recent studies on patients with compressive neuropathy and digital 
nerve laceration, but the mechanism of action is still not completely elucidated. 
Moreover, more clinical data are required before electrical stimulation will become a 
mainstream therapy, especially for the assessment of possible risk. All these therapies 
were performed at low frequency, such as 20 Hz. 
Indeed, EMF are also emitted by several common electrical devices, for example, 
mobile phones, emitting EMF at an intensity of 50 Hz. Epidemiologic studies (Funk 
and Monsees, 2006; Gürler et al., 2014) evidenced the risk of EMF exposure for the 
onset of neurodegenerative diseases and for different type of tumors (Carpenter, 
2013), such as schwannomas. Several data obtained from clinical studies 
corroborated such as pathogenic correlation (Hardell et al., 2006; INTERPHONE 
Study Group, 2011). However, the topic is very current, given the large diffusion of 
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electrical devices potentially emitting EMFs, and is important to underlie that the 
work frequencies is a key point for the therapy. 
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Aims 
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PNS diseases are a class of heterogeneous pathologies for which there are poor and 
unreliable therapies. Probably, this may be in consequence of their heterogeneic 
mechanisms and likely unknown etiology. Nowadays, the treatments are often 
symptomatic and there are no specific drugs that can lead to the full nerve recovery. 
The identification of specific and novel therapeutic approaches is a medical need. 
Although is difficult, given the complicated mechanism at the bases of the pathologies. 
In this light, the identification of the molecular mechanisms regulating the SCs 
development, maturation and regeneration is fundamental for the comprehension of 
possible therapeutic approaches. 
Several different pathways are involved in the control of SCs origin, development and 
maturation processes, and in this scenario the main aim of this thesis was to shed light 
on three different but correlated signaling: the SRC/FAK singaling, the Hippo pathway 
and the GABAergic signaling. 
Therefore, the studies reported and discussed in this thesis can be subdivided in three 
experimental aims: 
1.   the study of SRC/FAK pathway and their interaction with neuroactive steroid 
ALLO, known to have a role in the myelination process, via the GABA-A R; 
2.   the study of the physical stimulation by EMF of the SCs, deepening the study 
of Hippo signaling and YAP/TAZ pathway as key regulator of SCs. 
3.   the study of the GABAergic system, through the identification of the mRNA 
expression profile in conditional knock out mice for the GABA-B1 R, that 
specifically lack GABA-B1 R in SCs. 
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The 1st aim has been investigated in chapter 1 and will discuss how ALLO can affect 
different SC features, such as motility, migration and myelination, via the activation of 
SRC/FAK pathway. ALLO is important for SCs myelination process as well as 
SRC/FAK are important for cell proliferation. Therefore, the aim of this chapter is to 
highlight the impact of this novel mechanism on the maturation and myelination of SCs. 
Merlin is involved in the control of SCs cytoskeleton organization and proliferation. 
Mutations in NF2 gene leads to the onset of the Neurofibromatosis. EMF stimulation 
can impact on different SCs features such as cytoskeleton rearrangements, proliferation 
and migration properties, via NF2 regulation and the Hippo pathway. The 2nd aim has 
been investigated in chapter 2 and will discuss how the exposure of EMF, as a kind of 
mechano-stimulation, may impact on the oncogenic transformation of SCs. The aim is 
to identify possible pathogenic contributory causes of Merlin changes. Moreover, the 
involvement of the novel pathways Hippo and YAP/TAZ will be also considered. 
GABA-B1 is important for SCs myelination. This has been shown by means of 
conditional GABA-B1 knock out mice, where the transcriptomic profile shows a 
consistent amount of up- or downregulated genes and miRNAs. MiRNAs induce post-
translational modification probably involved in the myelination process. The 3rd aim 
has been investigated in chapter 3 and will discuss the expression profile and miRNAs 
in GABA-B1 conditional knock out mice, with specific deletion of GABA-B1 R in SCs. 
The aim is to identify novel possible targets, including miRNAs, that may be 
downstream GABA-B1 Rs in SCs. 
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Materials and Methods 
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Animals 
For the experiments discuss in Chapter 3, GABA-B1fl/fl  (Haller et al., 2004) mice were 
crossed with P0-Cre deleter mice (Feltri et al., 1999) to obtain mice. Which were then 
back-crossed with GABA-B1fl/fl mice. The resulting P0-Cre/GABA-B1fl/fl mice, with 
specific deletion of GABA-B1 in Schwann cells, were chosen as experimental group 
(P0-Cre/GABA-B1fl/fl), and were compared with GABA-B1fl/fl mice, chosen as control. 
Experiments were conducted on 3-month-old male mice. All experiments were done 
according to institutional guidelines and in compliance with the policy on the use of 
animals approved by the European Communities Council Directive (2010/63/UE) and 
the Italian law on the use of animals for scientific studies (D.Lgs 26/2014). 
Rat Schwann cells primary cultures 
For the experiments discuss in  1st and 2nd chapters, rat SCs culture were obtained by the 
method of Brockes (Brockes et al., 1979) with minor modifications (Magnaghi et al., 
2007). Sciatic nerves from 3-day old rats were digested with 1% collagenase and 0,25% 
trypsin (Sigma-Aldrich, Italy), then filtered through a 30 µm nylon membrane and 
centrifuged 10 min at 280 g. Pellets were suspended in DMEM (Dulbecco modified 
eagle medium - Euroclone, Italy) plus 10 % FBS (fetal bovine serum - Life 
Technologies Italia, Italy) and were plated on 35 mm Petri dishes. After 24 h, the 
medium was supplemented with 10 µM arabinoside C (Sigma-Aldrich, Italy) then after 
48 h the cultures were treated with a stream of cold DMEM-FBS 10%. The remaining 
cell were plated in DMEM-FBS 10% plus 10 µM forskolin (Sigma-Aldrich, Italy) and 
200 µg/mL BPE (bovine pituitary extract - Invitrogen, Italy). Cells became confluent 
in 10 days. Immunopanning for final purification was carried out incubating the cells 
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30 min with mouse anti rat Thy 1.1 antibody (Serotec, Italy) followed by 500 µL of 
baby rabbit complement (Cedarlane, Canada). Cell suspension was seeded on 60 mm 
petri dishes (9x104 cells/Petri) and maintained in DMEM, 10 % FBS, 2 µM forskolin, 
200 µg/mL BPE. At the third in vitro passage, SCs were treated for 48 h with 4 µM 
forskolin, then used for experiments. 
EMF 
For the experiments discuss in the 2nd chapter rat SCs were plated and treated with EMF 
at 50 Hertz (Hz) and 0.1 Tesla (T) for 10 min at 37 °C, then were used at different time 
points, according the specific experimental assays. SCs used as control were plated in 
same culture conditions, without EMF exposure. 
Pharmacological treatments 
For the experiments discuss in the 1st chapter rat SCs were treated for the indicated time 
with 10-6 M ALLO; a micromolar concentration was chosen to exclude any possible 
involvement of GABA-mediated endogenous activity. To test SCs growth, migration 
and chemotaxis SCs were treated with ALLO alone or ALLO plus 10-5 M PP2 (4-
amino-5-(4-chlorophenyl)-7-(dimethylethyl)-pyrazolil-[3,4-d]pyrimidine) and 
analysed at 2, 6, 24 or 48 h, lasting until 6 DIV in the long-term SCs assay. 
Concentration of GABAergic agonist/anatagonist were chosen based on previous 
experience (Magnaghi et al., 2007; Perego et al., 2012). To analyse the role of actin 
dynamics, the SCs were incubated for 1 h with cytochalasin D2 x 10-6 before a 30 min 
ALLO incubation. All drugs were from Sigma. Controls cultures were treated with 
vehicle (ethanol). 
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Immunofluorescence (IFL) and confocal scanner laser microscopy 
For the experiments discuss in the 1st chapter, rat SCs were seeded on slides in 12-
multiwell plates (15x103 cells/well), treated for 24 h with 10-6 M ALLO or 10-6 M 
ALLO plus 10-5 M PP2, then fixed in 4 % paraformaldehyde and processed for 
immunostaining. SCs purity (more than 98 %) was tested with a specific antibody 
against glycoprotein P0 (Magnaghi et al., 2007). Phalloidin-FITC staining of f-actin 
(1:250 – Sigma Aldrich, Italy) was used to reveal SCs cytoskeleton. Slides were 
incubated overnight at 4 °C in PBS (phosphate buffer saline- Euroclone, Italy), 0,25 % 
BSA (Bovine serum albumin – Sigma Aldrich), 0,1 % Triton X-100 and the specific 
primary antibody. The following day, slides were washed and mounted using 
VectashieldTM (Vector Laboratories. Burlingame, CA, USA). Nuclei stained with DAPI 
(40,6-diamidino-2-phenylindole).  
For the experiments discuss in the 2nd part of the results section, anti-NF2 antibody 
(1:500, Santa Cruz Biotecnology Inc, USA) and anti S100 protein (1:200, Sigma, Italy). 
The following day, the slides were washed two times and incubated 2 h at room 
temperature with Alexa-488 (green) or Alexa-594 (red) specific secondary antibody 
(1:800, Gibco-Life Technologies, Italy). After washing, slides were mounted using 
VectashieldTM (Vector Laboratories. Burlingame, CA, USA) and nuclei stained with 
DAPI. 
Controls for the specificity of antibodies included a lack of primary antibodies. Confocal 
microscopy was carried out using a Zeiss LSM 510 System (Oberkochen, Germany). 
Proliferation assay 
For the experiments discuss in the 1st and 2nd chapters, proliferation assay on SCs was 
performed using an automated cell counter (Luna; Logos Biosystems Inc, USA); 10.000 
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cells were plated into 35 mm petri dishes and collected after 6, 24, 48 and 72 h, with 
trypsin 0,05 %-EDTA (Ethylendiaminetetraacetic acid) 0,02 % in PBS (Euroclone, 
Italy). The cells suspended in DMEM were then counted with the vital stain Trypan 
blue (Logos Biosystems Inc, USA), which stains only death cells. 
Migration and chemotaxis assays 
For the experiments discuss in the 1st chapter a wound healing assay was performed 
making a scratch on the bottom of the petri containing SCs, then the medium was changed 
with fresh medium plus mytomicin 50 ng/mL (Sigma- Aldrich, Italy) to counteract cell 
proliferation and the cells exposed to EMF or 10-6 M ALLO and 10-6 M ALLO plus 10-5 
M PP2, respectively. Cells were then photographed with a scanning microscope (Axiovert 
200, Zeiss) at different time points: 2, 6, 24, 48 h and for the EMF experiments also at 72 
h after the scratch (t=0). Pictures were acquire using MetaVue software and the distances 
between cell fronts were measured with Image-ProPlus 6.0 (MediaCybernetics, USA), 
considering at least nine measurements from the top to the bottom. 
For EMF experiments, treated in the 2nd chapter, migration was also tested by the 
Boyden chamber assay (chemotaxis) using a 48-well Boyden’s chamber, according to 
the manufacturer’s instructions (Neuroprobe, USA). Cells were exposed to EMF, also 
in the presence of cyclodextrin 5 mM (as well as the migration assay). In all, 28 µL of 
control medium (DMEM) or DMEM/FBS 1 % was placed in the lower compartment of 
the chamber, as chemoattractants. The open-bottom wells of the upper compartment 
were filled with cells (105 cells/well), collected by trypsin and suspended in DMEM 
plus 0,1 % BSA (Sigma- Aldrich, Italy). Cells migrate through a pre-coated membrane 
with gelatin (0,2 mg/mL in PBS, 5 days at 4 °C). After migration (overnight, 37 °C), 
cells adherent to the underside of the membrane were fixed by methanol and stained 
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according to the Diff-Quik kit (Biomap, Italy). For quantitative analysis, cells were 
observed and counted using a x40 objective on an optical microscope. Three random 
objective fields were counted for each well and the mean number of migration cells 
was calculated. 
RNA extraction and qRT-PCR analysis 
For the experiments discuss in the 2nd chapter RNA samples were extracted using Trizol 
(Gibco-Life Technologies, Italy) according to the manufacturer’s protocol, then 
quantified with NanoDrop2000 (ThermoScientific, USA). Pure RNA was obtained after 
DNAse treatment with a specific kit (Sigma-Aldrich, USA). The retro-transcription 
reaction was carried with RT Iscript Supermix 5x (Bio-Rad, Italy) on 1 µg of purified 
RNA and the product was used to make qRT-PCR assay. Primers were designed by 
QuantPrime software (AG Bioinformatics Max Planck, Postdam, Germany). The 
following primers were used: Nf2: FW5’-ACGATGGCCAATGAAGCTCTGATG-3’, RW5’-
TGGCCTTGATTCGCTGCATCTC-3’; P0: FW5’-CCTGCTCTTCTCTTCTTTG-3’, RW5’-CACAGCACCATAGACTTC-3’; 
Pmp22: FW5’-TCCTGTTCCTTCACATCG-3’, RW5’-TGCCAGAGATCAGTCCTG-3’; a-tubulin: FW5’-
TCGCGCTGTAAGAAGCAACACC-3’, RW5’-GGAGATACACTCACGCATGGTTGC-3’; b2-microglobulin: FW5’-
TGCTTGCAGAGTTAAACACGTCAC-3’,  RW5’-TTACATGTCTCGGTCCCAGGTG-3’. 
The qRT-PCR was performed by measuring the incorporation of SYBR Green dye 
(Bio-Rad, Italy) on CFX 96 Real Time System-C1000 thermal cycler (Bio-rad, Italy). 
Data analysis was performed using the CFX Manager 2.0 software (Bio-rad, Italy), 
based on DDCt method for the relative quantification. The threshold cycle number (Ct) 
values of both the calibrator and the samples of interest were normalized to the Ct of 
the endogenous housekeeping genes. As calibrator, we used the RNA obtained from 
control sample. 
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Protein extraction and western blot analysis 
Protein samples were extracted from rat SCs in lysis buffer (PBS, 1 % Nonidet P-40 
and 1 mM EDTA; all from Sigma-Aldrich) containing a cocktail of protease inhibitors 
(Sigma-Aldrich, Italy). Samples were heated 20 min at 55 °C to denaturate secondary 
structure, then 15 ug was loaded onto a SDS-PAGE gel (Criterion TGX, Bio-Rad) and 
run at 200 V for 40 min in running buffer. Gels were electroblotted to Hybond 
nitrocellulose membrane (GE Healthcare, Italy). Membranes were blocked with 5 % 
not-fat dry milk (Bio-Rad, Italy) in PBS (Euroclone, Italy) before the incubation with 
the primary antibody diluted in the blocking solution. Primary antibodies used were 
rabbit anti-P0 (1:300, Sigma-Genosys, USA), rabbit anti-Pmp22 (1:300, Abcam, UK), 
mouse anti-NF2 (1:100, Santa Cruz Biotechnology, USA) and monoclonal anti-alpha-
Tubulin as reference (1:500, Sigma-Aldrich, Italy). To detect ERK2 and AKT levels, 
10 ug proteins were loaded and the antibodies used were the following: anti-phospho-
AKT Ser473 (1:1000, Cell Signaling Technology, USA), anti-AKT (1:1000, Cell 
Signaling Technology, USA), anti-phospho-ERK2 Tyr185/187 (1:1000, Cell Signaling 
Technology, USA), anti-ERK2 (1:5000 Santa Cruz Biotechnology, USA), anti-b-Actin 
(1:10.000, Sigam-Aldrich, Italy). In this case, results were standardized using b-Actin 
as a reference. Membranes were incubated with appropriated HRP-conjugated 
secondary antibodies (Millipore, USA). Immunocomplexes were revealed by 
enhanced chemiluminescence (ECL; GE Healthcare, Italy), visualized using the 
Chemidoc MP Imaging System (Bio-Rad, Italy) and analyzed by the Image Lab 
software (Bio-Rad, Italy). 
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Expression profile of Hippo pathway 
Rat Hippo signaling pathway RT2 Profiler PCR array (SuperArray Bioscience, USA) 
was used to profile the expression of 84 genes related to Hippo signaling. Total RNA 
was extracted from rat SCs, 2h after treatment, as described above. Single-stranded 
cDNA was synthesized from 2 µg of total RNA by using the SuperArray reaction ready 
first-strand cDNA synthesis kit. The cDNAs were mixed with SuperArray RT2 Real 
time SYBR green/ROX PCR master mix and real-time PCR performed in accordance 
with the manufacturer’s instructions. Thermal cycling and fluorescence detection were 
performed using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, 
Italy), then the expression of Hippo signaling regulated transcripts was compared 
between groups. 
  
85 
 
Genotyping 
Animals genotype was determined by PCR analysis on genomic DNA, extracted from 
tails, sciatic nerves and liver using microLYSIS®–Plus (Microzone Limited, Haywards 
Heath, UK), following manufacturer’s protocol. Used primers are reported in the table 
below (Table 3). PCR reaction with CRE-1 and CRE-2 primers on mice tails extracts 
allowed to determine which mice expressed the CRE recombinase; reactions with P5 
and P6 on mice tails extracts allowed to determine which mice presented inserted 
sequences in the GABA-B1 gene. Lastly, post-mortem reactions with P7 and P8 on 
sciatic nerve and liver extracts allowed to verify the GABA-B1 exon VII and VIII 
specific deletion in SCs (Faroni et al., 2014a). PCR was performed in a standard reaction 
mix under the following conditions (30 cycles): 94°C for 30 s; 56°C for 1 min; 72°C 
for 1 min. A final extension step at 72°C for 10 min was performed. The amplified 
products were analyzed on 1.5% agarose gels.  
Gene  (5’-3’) 
CRE1 5’-CCACCACCTCTCCATTGCAC-3’ 
CRE2 5’-GCTGGCCCAAATGTTCGTGG-3’ 
P5 5’-TGGGGTGTGTCCTACATGCAGCGGACGG-3’ 
P6 5’-GCTCTTCACCTTTCAACCCAGCCTCAGGCAGGC-3’ 
P7 5’-ATCTCTTCCTTGGCCTGGGTCTTTGCTTCGCTCG-3’ 
P8 5’-GGGTTATTTGAATATGATCGGAATTCCTCGACT-3’ 
 
Table 3 Primers used for genotype analysis on genomic DNA 
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Mouse SCs and DRG neurons primary cultures 
SCs cultures were obtained from sciatic nerves of 3-month-old mice. Nerve was digested 
with 0,0625% (w/v) collagenase Type IV (Worthington Biochemical, Lakewood, NJ), 
dispase (0,5 mg/mL; Life Technologies Italia, Italy) and Trypsin (2,5 mg/mL; 
Worthington Biochemical, Lakewood, NJ), then mechanically dissociated with a pipette, 
filtered through a 100 µM filter (BD Biosciences, San Jose, CA) and centrifuged 5 min 
at 900 rpm. Pellets were re-suspended in culture medium composed by DMEM 
(Euroclone, Italy), 10% FBS (Life Technologies Italia, Italy), 2 % insulin growth factor-
1 (IGF-1) and 2 µM forskolin. The cell suspension was then seeded on 60 mm petri dishes 
and grown in presence of 2 µM forskolin at 37°C, 5% CO2, and 95% humidity. Forskolin 
was increased 48 hours before the experiments to 4 µM final concentration.  
DRG neurons cultures were obtained from the spinal cord of 3-month-old mice. The 
DRGs were dissociated incubating in Ham’s F12 medium (Life Technologies Italia, 
Italy) containing 0,125% (w/v) collagenase Type IV (Worthington Biochemical, 
Lakewood, NJ), then treated with 0,25% (w/v) Trypsin (Worthington Biochemical, 
Lakewood, NJ). The dissociated DRG neurons were filtered through a 100 µM 
membrane (BD Biosciences) and centrifuged 5 min at 500 rpm. Cells were then 
resuspended in Ham’s F12 and purified on a gradient of 15% (w/v) BSA (Sigma-
Aldrich, Italy). Dissociated neurons were resuspended in modified BSM (Bottenstein 
and Sato) medium (F12 medium plus 100 µM putrescine, 30 nM sodium selenite, 20 
nM progesterone, 1 mg/mL BSA, 0,1 mg/mL transferrin, and 10 pM insulin, all Sigma-
Aldrich) and 50 ng/mL nerve growth factor (NGF - Millipore, Italy). Cell suspension 
of DRG neurons was seeded on a 35 mm petri dish coated with poli-L-lysin and laminin 
(Sigma-Aldrich) then maintained at 37 °C, 5% CO2, and 95% humidity. 
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Transcriptome microarray analysis  
Total RNA was extracted from mouse SCs and DRG neurons with DirectZol kit 
(Euroclone, Italy). RNA quantity was determined by the NanoDrop ND-2000 (Thermo 
Scientific, Italy). The RNA integrity was determined by the RNA 28S/18S ratio using 
the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Then samples 
were labeled and hybridized to the Affymetrix GeneChip Mouse Gene 2.0.ST Arrays 
(Santa Clara, CA) following the manufacturer's instructions. Experiments were due at 
the facility of Fondazione Istituto FIRC di Oncologia Molecolare (IFOM, Italy). 
Scanned microarray images were analyzed using the Affymetrix Gene Expression 
Console with the robust multiarray average normalization algorithm. 
Microarray Data Analysis  
Affymetrix data analysis was done in the R statistical environment using “oligo” and 
“limma” packages. Heat maps and scatter plots were generated using the statistical tools 
provided by the R and Bioconductor projects. Database mining analysis was performed 
by downloading the Gene Expression Omnibus (GEO) microarray data set from the 
National Institutes of Health NCBI GEO database and examining the expression levels 
of genes of interest and housekeeping genes as reported. 
Data analysis and statistics 
Data were statistically evaluated by GraphPad Prism 4.00 (San Diego, USA). Statistical 
significance between groups was determined by means of an unpaired Student’s t-test, 
one-way ANOVA with Tukey’s post-test, or by two-way ANOVA using Bonferroni’s 
post-hoc test. P-values < 0.05 were considered as significant. 
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Results and discussion 
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CHAPTER 1 
SRC and phospho-FAK kinases are activated by ALLO 
promoting SC motility, morphology and myelination 
SC maturation and development require the complementary activation of different 
intracellular signaling pathways. The SRC/FAK are important for SCs for the control 
of adhesion, motility and migration capability. ALLO, synthetized by SC, acts in an 
autocrine way on SC proliferation and motility, necessary for normal nerve 
development, maturation and regeneration.  
In this chapter, we performed experiments in order to pursue the aim 1 of this thesis 
regarding the hypothesis that the mechanism underlying the ALLO actions on SCs 
involve the signaling intermediates SRC and FAK. 
ALLO regulates SC morphology and motility 
Data previously collected in our and others laboratories demonstrated that ALLO 
increases SC proliferation, particularly via GABA-A mediated mechanisms (Faroni et 
al., 2012; Perego et al., 2012). First, the cells were exposed to ALLO 10-6 M for 24 h 
and it was found that in vitro treatment with ALLO 10-6 M induced SCs morphological 
rearrangements, giving to these cells the capability to assume the typical spindle-shaped 
morphology (Figure 14a). This effect was counteracted by the co-treatment with the 
selective inhibitor of SRC kinase, PP2 10-5 M, [PP2 10-5 M concentration was chosen 
on the base of previous experiments (Zheng et al., 2012). Indeed, SCs co-treated with 
ALLO and PP2 for 24 h showed changes in morphology, resembling flattened cells 
(Figure 14a). This data suggested the involvement of SRC signaling cascade in the 
control of the ALLO-induced changes in SCs morphology. A direct involvement of Src 
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was further corroborated by phalloidin IFL. ALLO proved able to enhance the typical 
spindle-shaped morphology of SCs, as shown by stress fibers immunostaining (Figure 
14b, central panels and Figure15). Furthermore, ALLO induces formation of radial 
lamellipodia in SCs (Figure 13b, central panels and Figure 14). The simultaneous PP2 
co- treatment changed the SCs morphology towards an enlarged and flattened 
phenotype, in which the lamellipodia were significantly reduced (Figure 14b, lower 
panels and Figure 15), still suggesting a strong involvement of SRC in the ALLO- 
regulated SCs adhesion.  
Furthermore, to test the long-term effects of ALLO and PP2 (i.e. Src involvement) on 
morphology and adhesion, the SCs cultures were treated and analyzed at 6 DIV. 
Exposure to ALLO 10-6 M still promoted the growth and the characteristic spindle-
shaped morphology (Figure 14c), whereas the SCs culture exposed contemporary to 
ALLO and PP2 10-5 M appeared suffering and decreased in number (Figure 14c).  
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Figure 14 ALLO regulates SCs morphology. (a) Light microscopy images of SCs treated for 24 h with ALLO 10-6 
M and ALLO plus the Src inhibitor PP2 10-5 M. ALLO treatment induced the typical SCs spindle-shaped morphology 
that changed versus flattened cells following PP2 exposure. CTR, control cultures exposed to vehicle. Bar 10 µm. 
(b) ALLO treatment induced SCs morphological rearrangements in actin cytoskeleton, as assessed by 
immunopositivity for f-actin (phalloidin-FICT, in green). After 24 h, ALLO 10-6 M enhanced the stress fibers and 
radial lamellipodia formation in SCs (white asterisks in central panels), whereas the simultaneous PP2 10-5 M co-
treatment changed the SCs, enlarging shape and reducing lamellipodia (lower panels). Dapi (in blue). Bar 10 µm. 
(c) ALLO and PP2 also exerted long- term effects (at 6 DIV) on SCs morphology and adhesion. Exposure to ALLO 
10-6 M, indeed, promoted the characteristic spindle-shaped morphology (Figure 14c central panel; see also cell 
details at higher magnification). Conversely, SCs simultaneously exposed to ALLO 10-6 M plus PP2 10-5 M 
degenerated and decreased in number (Figure 14c right panel; see cell details at higher magnification). CTR, control 
cultures exposed to vehicle. Bar 10 µm. 
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Figure 15 After 24 h, ALLO 10−6 M treatment induced SCs morphological rearrangements in actin cytoskeleton, as 
assessed by immunopositivity in green for f-actin (phalloidin-FICT, upper right panel). ALLO 10−6 M plus 4-amino-5-
(4-chlorophenyl)-7-(dimethylethyl)-pyrazolil-[3,4-d]pyrimidine (PP2) 10−5 M co-treatment enlarged SCs shape and 
reduced lamellipodia (lower left and right panels). CTR, control culture (upper left panel). Dapi in blue. Bar 10 µm. 
Then, it was interesting to analyse whether ALLO may control SC migration. To assess 
this hypothesis, we designed a wound-healing assay on a SCs monolayer treated with 
ALLO 10-6 M was performed. A great number of SCs were able to repopulate the 
wounded region within 24 h (Figure 16b), achieving a complete closure of the two sides 
at later time, 48 h (Figure 17). ALLO 10-6 M exposure induced a stimulation of SCs 
migration (Figure 16b) compard to controls (Figure 16a), that was significantly 
increased (p < 0.001; F = 30.72) at 2, 6 and 24 h after treatment (Figure 16d). This effect 
was significantly blocked (p < 0.001; F = 30.72) by the simultaneous co-treatment with 
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PP2 10-5 M (Figure 16c), vs controls (Figure 16a), confirming that ALLO stimulation 
might be via Src activation. Furthermore, a 24 h ALLO treatment induced a significant 
increase (p < 0.001; F = 30.72) in SC response to chemotactic agents. The Boyden’s 
chamber assay, indeed, indicated that the ALLO- exposed SCs were responsive to a 
chemotactic agent, such as FBS. The number of migrating cells was significantly 
augmented (p < 0.05; F = 78.36) after 24 h treatment with ALLO 10-6 M. These findings 
suggested that ALLO makes SCs more responsive to the chemoattractants (Figure 16e). 
The simultaneous co-treatment of SCs for 24 h with ALLO 10-6 M plus PP2 10-5 M 
significantly reduced (p < 0.01; F = 78.36) the response to FCS, still evidencing that 
SRC is involved in the ALLO’s induced chemoattractant responsivity of SCs.  
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Figure 16 ALLO regulates SCs’ motility and chemoattractant responsivity. (a) Microscopic images of control 
(CTR) SCs cultures showing a scratch on the bottom of the well (t 0 h). Medium was replaced and cell proliferation 
was blocked with 50 ng/mL mitomycin. SCs were photographed at 2 (t 2 h), 6 (t 6 h) and 24 h (t 24 h) after the 
scratch. (b) Microscopic images of SCs undergoing a scratch on the bottom of the well (t 0 h). Medium was replaced 
and cell proliferation was blocked by adding 50 ng/mL mitomycin. SCs were treated with ALLO 10-6 M and analysed 
at t 2 h, t 6 h and t 24 h. (c) Microscopic images of SCs undergoing a scratch on the bottom of the well (t 0 h). 
Medium was replaced and cell proliferation was blocked by adding 50 ng/mL mito- mycin. Then SCs were treated 
with ALLO 10-6 M plus PP2 10-5 M and analysed at t2h, t6h and t24h .Bar10 µm. (d)Histograms of cell distance (µm) 
of SCs treated, respectively, with ALLO 10-6 M (light dotted columns) or ALLO 10-6 plus PP2 10-5 M (grey dotted 
columns) versus controls (CTR, black columns). Treatments with ALLO produced a significant increase in cell 
migration (***p < 0.001) at 2, 6 and 24 h, completely restored by the treatment with PP2 10-5 M (***p < 0.001). 
The distance (µm) was calculated as difference between measurements of empty space at time 0 and other time points 
(2, 6 and 24 h). Data are expressed as the mean ±SEM (N = 3) of 3 independent experiments. Two-way ANOVA 
95 
 
using Tukey’s multiple comparison post hoc test was used for statistical analysis. F = 30.72 (e) SCs exposure to 
ALLO significantly increases the responsiveness to the chemotactic agent FCS 1%. Migrating cell number (per well) 
of SCs treated, respectively, with ALLO 10-6M (white column, *p < 0.05) or ALLO 10-6 M plus PP2 10-5 M (grey 
dot column, **p < 0.01) was calculated after 18 h versus controls (CTR, black column). Data are expressed as the 
mean ±SEM (N = 3) of 3 independent experiments. One-way ANOVA using Tukey’s multiple comparison post hoc 
test was used for statistical analysis. F = 78.36. 
 
Figure 17 Microscopic images at 48 h (48 h) of SCs undergoing the scratch assay. SCs in culture achieved the 
complete closure of the two sides at 48 h, independently of treatment: vehicle (control, CTR), ALLO 10−6 M alone or 
in combination with PP2 10−5 M. Bar 10 µm. 
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ALLO actions in SCs involve the modulation of SRC and p-FAK pathways 
Given the importance of SRC and FAK protein kinases it was interesting to investigate 
wether these features, may be involved in the cytoskeleton reorganization and migration 
changes of SC after ALLO treatment.  
First, ALLO treatment increased the expression of total SRC and p-SRC, respectively, 
after 30 and 60 min. Data were normalized for actin (50 kDa) housekeeping protein 
(Figure 18a), which levels from different experiments were within 10% of each other. 
Quantitative evaluation at 30 min showed a significant decrease in p-SRC/ SRC ratio (p 
< 0.05; F = 6.61), likely because of an increase in total SRC (Figure 18b). Then, at 60 
min, a significant increase in p- SRC/SRC ratio (p < 0.05 ̧ F = 16.69) was observed; this 
was because of an increase in p-SRC (Figure 18c). Altogether, data confirmed a decrease 
in p-SRC/SRC ratio at 30 min, then an increase at 60 min, suggesting that ALLO lightly 
stimulates SRC synthesis, in turn inducing its phosphorylation (Figure 18b).  
FAK as a signaling protein downstream SRC activation. Therefore, it was investigated 
the effect of ALLO on FAK expression. FAK showed a protein profile in line with SRC. 
Indeed, the levels of total p-FAK were increased after 30 and 60 min post ALLO 
treatment (Figure 18a). The quantitative evaluation at 30 and 60 min after actin 
normalization) showed a significant increase in p- FAK/FAK ratio (p < 0.05; F = 6.71, 
30 min; F = 18.01, 60 min), mainly because of an increase in p-FAK at both time points 
considered (Figure 18d and e). These results agree with the hypothesis that FAK 
phosphorylation is likely downstream SRC activation.  
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ALLO modulation of SRC and p-FAK pathways partially involves GABA-A 
dependent mechanism 
To speculate on the receptor mediating the ALLO-dependent activation of SRC and FAK, 
the attention was focused first on SRC at 30 min, that is proved to be the early time-point 
showing significant modifications. Moreover, trying to mimic ALLO effects via GABA-
A R, the SCs were treated with muscimol 10-3 M alone (selective GABA-A agonist) or 
ALLO 10-6 M plus bicuculline 10-4 M (selective GABA-A antag- onist) respectively. 
Muscimol treatment decreased the p-SRC levels (Figure 19a). The quantitative analysis, 
after actin normalization, confirmed the significant (p < 0.05; F = 8.92) decrease in p-
SRC with muscimol, in turn producing a significant decrease in the p-SRC/SRC ratio (p 
< 0.05; F = 8.92) (Figure 19b). In agreement with data above (see Fig. 19b), the treatment 
with ALLO significantly decreased the p-SRC/SRC ratio (p < 0.05; F = 8.92), supporting 
the GABA-A mediated inactivation of this pathway (Figure 19b). Furthermore, co-
treatment with ALLO plus bicuculline counteracted the ALLO’s effects on SRC and p-
SRC respectively (Figure 19a). Quantitative evaluation (after actin normalization) 
showed that the p-SRC/SRC ratio after bicuculline treatment was like controls (Figure 
19b). This data further suggested that ALLO acts via a GABA-A activation.  
Secondly, the quantitative analysis, after actin normalization, showed that ALLO 
significantly (p < 0.05; F = 14.85) increased the p-FAK and p-FAK/FAK levels (Figure 
19d). Muscimol 10-3 M alone did not produce any significant change, suggesting that 
GABA-A mediated mechanisms should not be involved in this control. The 
simultaneous treatment with ALLO plus bicuculline 10-4 M, however, potentiates 
significantly (p < 0.05; F = 14.85) the ALLO-induced rising of p-FAK and p-FAK/FAK 
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ratio (Figure 19d), suggesting that ALLO may be re-addressed towards different signaling 
pathways, likely via PR or the putative membrane progesterone receptor (mPR).  
 
Figure 18 ALLO administration to SCs results in Src and phospho-FAK (p-FAK) activation. (a) Images are 
representative of western blot analysis for the total and phosphorylated forms of FAK (125 kDa), and Src (60 kDa), 
at 30 and 60 min after treatment with ALLO 10-6 M. Actin was used as housekeeping. CTR, controls. Quantitative 
histograms of the ratio Src/actin, p-Src-actin and p-Src/ Src at 30 min (b) or 60 min (c) after treatment with ALLO 
10-6 M (grey columns) versus control (CTR, black columns). Quantitative histograms of the ratio FAK/actin, p-
FAK/actin and p-FAK/FAK at 30 min (d) or 60 min (e) after treatment with ALLO 10-6 M (grey columns) versus 
control (CTR, black columns). Data are expressed as the mean ±SEM (N = 6) of 3 independent experiments. One-
way ANOVA followed by Tukey’s multiple comparison post hoc test (*p < 0.05 vs. controls, CTR) was used for 
statistical analysis. F=6.61(b);F=16.69(c);F=6.71(d);F=18.01(e). 
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Figure 19 ALLO modulation in SCs partially involves GABA-A-dependent mechanisms. (a) Images are 
representative of western blot analysis for the total and phosphorylated form of FAK (125 kDa), and Src (60 kDa) 
after 30 min treatment with: ALLO 10-6 M; ALLO 10-6 M + bicuculline 10-4 M; muscimol 10-3 M. Actin was used as 
housekeeping. CTR, controls. (b) Quantitative histograms of the ratio Src/actin, p-Src/actin and p-Src/Src at 30 min 
after treatment with ALLO 10-6 M alone (grey columns), ALLO 10-6 M + bicuculline 10-4 M (diagonal line columns) 
or muscimol 10-3 M alone (vertical line columns) versus control (CTR, black columns). (c) Quantitative histograms 
of the ratio FAK/actin, p-FAK/actin and p-FAK/ FAK at 30 min after treatment with ALLO 10-6 M alone (grey 
columns), ALLO 10-6 M + bicuculline 10-4 M (diagonal line columns) or muscimol 10-3 M alone (vertical line 
columns) versus control (CTR, black columns). Data are expressed as the mean ±SEM (N = 6) of 3 independent 
experiments. One-way ANOVA followed by Tukey’s multiple comparison post hoc test (*p < 0.05 vs. controls, CTR) 
was used for statistical analysis. F = 8.92 (b); F = 14.85 (c). 
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ALLO modulation of SRC and p-FAK pathways depends by actin remodeling  
The qualitative analysis of western immunoblots showed that, a potent inhibitor of actin 
polymerization and cytoskeleton remodeling, cytochalasin D, induced an apparent 
ALLO potentiation of SRC protein levels (Figure 20a). In principle, this effect indicated 
that changes in actin cytoskeleton might strengthen ALLO’s action in SCs. However, 
the quantitative evaluation of p-SRC/SRC ratio showed no statistical significant 
changes following a 30-min ALLO treatment in the presence of cytochalasin D 2 x 10-6 
M (Figure 20b). Treatment with ALLO alone, indeed significantly decreased the 
pSRC/SRC ratio (p < 0.05; F = 3.97).  
Regarding FAK, a similar qualitative trend was observed (Figure 20a); Cytochalasin D 
treatment induced an increase in p-FAK levels (Figure 20a). Quantification of p-FAK 
and p-FAK/FAK ratio still confirmed the significant stimulation induced by ALLO (p 
< 0.05; F = 3.86), whereas no change in p-FAK/FAK ratio following cytochalasin D 
treatment was observed (Figure 20b).  
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Figure 20 ALLO modulation in SCs depends by actin remodelling. (a) Images are representative of western blot 
analysis for the total and phosphorylated forms of FAK (125 kDa), and Src (60 kDa), following a 30 min treatment 
with ALLO 10-6 M or ALLO 10-6 + cytochalasin D (CD) 2 x 10-6 M. Actin was used as house- keeping. CTR, controls. 
Quantitative histograms of the ratio Src/actin, p-Src/actin, p-Src/Src (b) and FAK/actin, p-FAK/actin and p-FAK/ 
FAK (c) at 30 min after treatment with ALLO 10-6 M (grey columns) or ALLO plus cytochalasin D 2 x 10-6 M (CD, 
squared columns) versus control (CTR, black columns). Data are expressed as the mean ±SEM (N = 6) of 3 
independent experiments. One-way ANOVA followed by Tukey’s multiple comparison post hoc test (*p < 0.05 vs. 
controls, CTR) was used for statistical analysis. F = 3.97 (b); F = 3.86 (c). 
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Discussion 
In accordance with previous observations (Perego et al., 2012), this work provides 
evidence that ALLO controls SCs motility and morphological changes, supporting 
proliferation. ALLO is also able to induce myelination, and these processes 
involve the activation of SRC and p-FAK signaling. Moreover, ALLO modulation 
of SRC and p-FAK pathways involves GABA-A dependent mechanisms and relies 
on actin rearrangements.  
It is known that ALLO, synthesized and/or metabolized in SCs, have an important role 
in the control of myelination, nociception and nerve regeneration (Magnaghi et al., 
2006c, 2010; Faroni and Magnaghi, 2011; Patte-Mensah et al., 2014). ALLO exerts a 
stimulatory action on the PMP22 levels in vitro (Magnaghi et al., 2006a; Melcangi and 
Panzica, 2009; Perego et al., 2012), inducing the in vivo myelination in injured adult 
and aged rats (Melcangi et al., 1999; Azcoitia et al., 2003). ALLO participates in the 
regulation of myelination program by controlling the expression of important 
transcription factors, such as KROX-20 and SRY-Box10 (SOX10) (Magnaghi et al., 
2007). In SCs, ALLO takes part in orchestrating these processes by activating integrated 
mechanisms that, in turn, involve the GABA synthesis, as well as the GABA-A and 
GABA-B receptors modulation (Faroni and Magnaghi, 2011; Procacci et al., 2012). 
Namely, through a PKA-dependent autocrine loop ALLO stimulates the GABA 
synthesis (Magnaghi et al., 2010), while through a GABA-A-activated PKC-dependent 
action, ALLO regulates the EAAC1 activity, providing glutamate as GABA precursor 
in SCs (Perego et al., 2012). However, other protein kinases, such as PKC-epsilon, seem 
to be involved in ALLO’s effects on SCs. Recently, it was suggested that PKC-epsilon 
may be regulated in DRG neurons by conditioned medium obtained from SCs treated 
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with 10-6 M ALLO (Puia et al., 2015) whether ALLO may alter PKC-epsilon directly 
in SCs is now under evaluation.  
ALLO acts mainly through the GABA-A receptor in a concentration-dependent manner 
(Majewska et al., 1986; Rupprecht and Holsboer, 1999; Lambert et al., 2003). In the 
low nano-molar range ALLO’s action is allosteric, enhancing the action of the natural 
ligand GABA, while in the micro-molar range, ALLO directly gates the GABA-A 
receptor channel (Callachan et al., 1987; Puia et al., 1990). However, the intrinsic 
cellular mechanisms regulating most of the ALLO-mediated processes are unknown. 
Therefore, this work speculated on the ALLO’s mechanisms that might affect the 
cellular and biological processes regulating SCs.  
Data in the literature evidenced the participation of SRC in the control of cell migration 
and differentiation (Zhao et al., 2003). In agreement with thus capacity of SRC, it was 
interestingly to investigate whether ALLO controls SCs morphology and motility via a 
SRC signaling. These findings corroborate the importance of SRC in the onset of 
peripheral myelination (Hossain et al., 2010).  
As previously reported, EAAC1 delivery on the SCs membrane is stimulated by ALLO 
and prevented by actin de-polymerization, suggesting that also EAAC1 participates in 
the control of the rapid ALLO-mediated effects on SC morphology and proliferation 
(Perego et al., 2012). These phenomena are likely exerted because ALLO can promote 
the selective EAAC1 binding to proteins tethering the transporter to the actin 
cytoskeleton. In SCs, ALLO accumulated actin at the leading edge and in the filopodia, 
whose number was significantly increased (Perego et al., 2012). In addition, here we 
proved that, beside EAAC1 involvement, the ALLO’s effects on actin rearrangements 
may involve SRC/p-FAK. It is important to underline that in the experimental model, 
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ALLO’s effects on actin remodeling did not entail any alteration in the actin protein 
levels, which remain within 10% variation among samples analyzed.  
Other progestagens were shown to be implicated in the control of actin polymerization 
and branching as well as in FAK complex formation. These effects seemed to be 
mediated via the classic PR. Interestingly, these phenomena may be relevant for 
neuronal plasticity and dendritic spine turnover (Sanchez et al., 2013). Nevertheless, 
the SRC/FAK signaling cascade might be implicated in the glial cells functions, albeit 
it was never completely studied in these cells, neither in the CNS nor in the PNS. Only 
FAK was shown to be required for proliferation, spreading and differentiation of SCs 
(Grove et al., 2007; Grove and Brophy, 2014). However, FAK does not seem to be 
required myelin maintenance of adult SCs, nor for re-myelination after nerve injury 
(Grove and Brophy, 2014). This suggests a role for FAK primarily in SCs development. 
However, in several models FAK was downstream SRC and upstream moesin 
activation (Sanchez et al., 2013). 
Taken together, these findings corroborate the hypothesis that the ALLO-mediated GABA-
A control of SCs may be responsible for the delayed differentiation observed in vivo, 
following neuroactive steroid treatment (Melcangi et al., 2000; Azcoitia et al., 2003). 
Beside the GABA-A involvement in the ALLO’s mediated changes of SCs, other 
mechanisms involving the mPRs or the metabotropic GABA-B Rs might participate in 
regulating some of the SC changes observed. Indeed, these findings show that SRC 
seems to be controlled directly by ALLO through a GABA-A dependent mechanisms, 
whereas FAK might be partially regulated via this receptor. Other signaling systems 
involving the classic PR or the membrane mPR receptors might be also considered as 
possible FAK regulators. In addition, some of the effects induced by ALLO might be 
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due to its retro-conversion in DHP and/or P, still interacting with the classic PR or non-
classic mPR, steroid receptors. However, the observation that ALLO-mediated effects 
on proliferation, chemotactic response and myelination are counteracted by the co-
treatment with the specific SRC inhibitor PP2 seem to exclude such a hypothesis.  
Finally, apart the well-known capability of ALLO in controlling PNS myelination 
(Melcangi et al., 1999; Azcoitia et al., 2003; Magnaghi et al., 2006a), ALLO may also 
regulates myelination and the internode length. Although it is difficult to determine 
whether such control is exclusively dependent on SRC activation, data from the 
literature support this relationship. Indeed, SCs from Lck -/- knock out mice (Lck, a 
lymphoid cell kinase belonging to the SRC kinase family) showed shorter and fewer 
internodes upon myelination, associated to delayed and altered myelination (Ness et al., 
2013). Given that, a functional relationship between the internodal length and nerve 
conduction velocity was proved (Wu et al., 2012), it was suggested that ALLO, likely 
via indirect mechanisms, may have important physiological functions in regulating the 
nerve conduction velocity in peripheral nerves.  
In conclusion, this study demonstrated the important role of the neuroactive steroid 
ALLO in regulating the SCs development and maturation. These effects are mediated 
mostly by GABA-A receptor and SRC/FAK signaling cascade, resulting in SCs actin 
remodeling, migration, chemoattractant responsivity and proliferation (Figure 20). The 
comprehension of these mechanisms may provide the basis for the control of SCs 
physiological processes and for the development of new therapies for the PN.  
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CHAPTER 2 
Tumor suppressor Nf2/Merlin drives SCs changes following 
EMF exposure through Hippo-dependent mechanism 
Mutations of the NF2 gene, encoding the tumor suppressor protein merlin where shown 
in sporadic and vestibular schwannomas affecting SCs. Several efforts have been 
addressed to identify possible factors, even environmental, that regulate neurofibromas 
development. 
In this chapter we performed experiments in order to pursue the aim 2 of this thesis 
investigating how the exposure of SCs to an EMF of 50 Hz, an environmental challenge 
able to modulate biological processes, can affect SCs features such as morphology, 
proliferation, migration and myelinating capability. 
Exposure to EMF induces changes in SC morphology and proliferation 
SCs primary cultures from 3-day-old rats were used for the experiments. These cells 
showed the peculiar spindle-shape morphology in vitro. Cell purity, more than 98%, 
was assessed performing immunostaining for the typical specific markers P0 and 
protein S100 (Figure 21a).  
To test the effects of EMF on SC biological features, EMF intensity of 50 Hz, 0.1T for 
10 min was applied (Figure 21b). EMF exposure induced morphologic rearrangements 
in actin cytoskeleton, which might be critical for SCs differentiation and myelination. 
SCs turn from a spindle- shaped to an enlarged phenotype, indicating a dysregulation 
in the differentiation program. In fact, cells exposed to the treatment resemble to the 
undifferentiated phenotype (Figure 21c).  
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The effects of EMFs on cell proliferation was evaluated in order to test whether EMF 
exposure may induce other SCs biological changes. Specifically, SCs count was 
evaluated in vitro at 6, 24, 48 and 72 h following EMF exposure (Figure 21d). The effect 
already present after 24 h became significantly evident at longer times, 48 and 72 h (P 
< 0.05). Furthermore, a second EMF exposure after 24 h strongly increased SCs 
proliferation at 48 and 72 h (Figure d), likely suggesting an additive effect of EMF on 
SCs proliferation. This effect was not dependent on a decrease in cell death. Indeed, 
EMF did not induce any sign of cell death or changes in cells viability at all time points 
considered, even after a double exposure (Figure 21e).  
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Figure 21 SCs change morphology and proliferation following EMF exposure. (a) Merge image of SC 
characterized by immunopositivity for P0 and S100 markers, respectively (anti-P0-594, in red; anti-s100-488, in 
green), showing a cell purity more than 98%. Nuclei were stained with DAPI, in blue. Scale bar 10 µm. (b) Scheme 
of the experimental model used. SCs were exposed to EMF of 50 Hz, 0.1 T, for 10 min, then cells were assayed for 
proliferation, migration, vitality, chemoresponsivity, morphology, western blot, qRT-PCR and RT2 profiler PCR. (c) 
EMF exposure induces SCs morphologic rearrangements in actin cytoskeleton, as assessed by immunopositivity for 
f-actin (phalloidin-FICT, in green). SCs turned from a spindle-shaped, characteristic of a more differentiated 
phenotype, to an enlarged shape, that better represent a SC in its proliferative state, suggesting alterations in the 
differentiation program. Nuclei were stained with DAPI, in blue. Scale bar 10 µm. (d) SCs proliferation was assessed 
at 6, 24, 48 and 72 h, following a single (dashed line) or double (dot line) EMF exposure. EMFs produced a 
significant (*P<0.05) increase in cell proliferation. Experiments were repeated at least three times and data 
expressed as cell number (×103). Two-way ANOVA using Bonferroni’s post hoc test was used for statistical analysis. 
(e) Percentage of SCs vitality was assessed at 6, 24, 48 and 72 h, following a single (white columns) or double (gray 
columns) EMF exposure, but no significant changes in SCs vitality were observed. Controls (CONTR, black 
columns). The values are means ± S.D. (N = 3). 
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SCs exposed to EMFs possess greater migratory and chemotactic 
After evaluating SC changes in morphology and proliferation a wound-healing assay, 
on a cell monolayer, and Boyden chamber assays, to measure chemotaxis, were 
performed. EMF exposure promoted the SC motility. Indeed, a great number of SCs 
were able to repopulate the wounded region within 24 h, achieving a complete closure 
of the two sides at later times, 48 and 72 h (Figure 22a). EMF exposure induced a 
significant increase (P < 0.05) in SC motility at 6 and 24h, corroborating the EMF effect 
on cell migration. The concomitant presence of mitomycin 50 ng/ml excluded any 
proliferative component on the gap closure. The effect was significantly counteracted 
(P < 0.05) by a pretreatment with cyclodextrin 5 mM (Figure 22c), a molecule used 
to produce changes in membrane cholesterol, thus indicating that a disorganization in 
lipid rafts and cell membrane architecture may alter the SC migratory response to the 
EMF. This is in accordance with the morphologic rearrangement in actin cytoskeleton 
seen in Figure 22c.  
SCs chemotactic response was then evaluated by mean of Boyden chamber assay. EMF-
exposed SCs were more responsive to a chemotactic agent, such as FBS (Figure 22d). 
The co-treatment with 5 mM cyclodextrin reverted the chemotactic migration to the 
control levels. This effect strongly suggested the hypothesis that an autocrine factor, 
tightly interacting with the cell membrane, may regulate the SCs development. Likely 
by this mechanism the SCs address their fate toward a proliferative state and in turn 
change their migration and chemotactic responsiveness.  
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Figure 22 SCs migration and chemoresponsivity are increased following 10 min EMF exposure. (a) Microscopic 
images of SCs cultures, exposed to EMF, in which a scratch has been done on the bottom of the well (t0). Medium 
was replaced and cell proliferation was blocked by adding 50 ng/ml mitomycin. SCs migrate after 2 (t2) and 6 (t6) 
h, closing the wound region within 24 h (t24). A complete closure was seen at 48 (t48) and 72 (t72) h. Scale bar 10 
µm. (b) Microscopic images of control SCs cultures, in which a scratch has been done on the bottom of the well. (t0). 
Medium was replaced and cell proliferation was blocked by adding 50 ng/ml mitomycin. SCs migrate after 2 (t2) 
and 6 (t6) h, less than in the treated SCs. Control SCs do not completely close the wound region in 24 (t24) h, they 
complete the closure of the wounded region in 48 (t48) h, more slowly than in the treated SCs. Scale bar 10 µm. (c) 
Histograms of cell distance (µm) of SCs exposed to 10 min EMF (EMF, white columns) versus controls (CONTR, 
black columns). EMFs produced a significant (*P o 0.05) increase in cell migration at 6 and 24 h. The distance (µm) 
was calculated as difference between measurements of empty space at time 0 and following time points (2, 6 and 24 
h). The values are means ± S.D. (N = 3). (d) Distance (µm) of SCs exposed for 6 h to 10 min EMF was significantly 
counterbalanced (*P o 0.05) by pre-treatment with cyclodextrin 5 mM (EMF+CDX, white column). Experiments 
and data were calculated versus controls (CONTR, black columns), as above. The values are means ± S.D. (N = 3). 
(e) A 10-min EMF exposure make the SCs significantly (*P o 0.05) responsive to the chemotactic agent FCS 1%. 
Migrating cell number (per well) of SCs exposed (EMF, white column) was calculated after 6 h, versus controls 
(CONTR, black columns). SCs co-treated with 5 mM cyclodextrin reversed the chemotactic response to the control 
levels (diagonal lines column). The values are means ± S.D. (N = 3). One-way ANOVA using Tukey's post-test was 
used for all statistical analysis. 
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Expression of myelin proteins P0 and PMP22 is changed in EMF-exposed SCs 
The increase in proliferation/migration observed was associated with a decrease in 
myelinating parameters. Overall, the gene expression of two specific myelin proteins of 
the PNS, the glycoprotein P0 and the PMP22, significantly dropped down (at least P < 
0.05) in SCs exposed to EMF at 2, 6 and 24 h (Figure 23a). In accordance, also the 
protein levels were significantly downregulated (P < 0.05), whereas the effects were 
acute at later times, 6 and 24 h post exposure (Figure 23b). Overall, the effects seemed 
to be larger for PMP22.  
Merlin levels are decreased in SCs exposed to EMFs 
Changes in the tumor suppressor Merlin are predictive of oncogenic transformations of SCs. 
After 2h of EMF exposure, the qRT-PCR analysis showed a significant 25% decrease in 
Merlin gene expression after treatment (compared to control; P < 0.05); this effect was not 
evident at later time points (Figure 23c). In accordance, Merlin protein levels were equally 
downregulated in SCs, as shown by the immunoblot in Figure 3d. Quantitative data 
confirmed a significant 25% downregulation (P < 0.05) of merlin protein levels 2h after EMF 
exposure, while no changes were observed at later time points (Figure 23d). Decreased levels 
of Merlin gene has been associated with defects of SC bipolar extension, according to the 
enlarged SC morphologic phenotype observed (Figure 21b). However, aside the decreased in 
the Merlin levels also a different cellular distribution was observed (Figure 23e). In SCs 
exposed to EMF, Merlin appeared more localized in the cytoplasm rather than in the nucleus 
(controls). Such an effect corroborated the loss of Merlin suppressor function, which 
necessarily would occur through a nuclear localization.  
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Figure 23 Myelin proteins (P0 and PMP22) and Nf2/Merlin are decreased following 10 min EMF exposure. (a) 
Relative quantification by qRT-PCR of mRNA levels, coding for proteins P0 and PMP22 respectively, showed a 
decreased expression at all time points considered, 2, 6 and 24 h. Data were normalized to the housekeeping genes 
α-tubulin and β2-microglobulin and expressed as difference (ΔΔCt) versus controls, then averaged for each 
experimental group. The columns control (CONTR, black) and EMF-exposed SC (EMF, white) were expressed as 
fold changes. The values are means ± S.D. (N = 3). *P < 0.05, **P < 0.01, ***P < 0.001. (b) Western blot analysis 
corroborated the decrease of P0 and PMP22 in EMF-exposed SCs (EMF, white columns), with significant effects at 
later times, 6 and 24 h (*P < 0.05). Data were normalized for α-tubulin, were expressed as percentage versus 
controls (CONTR, black columns). The values are means ± S.D. (N = 3). (c) Neurofibromin 2 (Nf2) mRNA levels 
were assayed by qRT-PCR, showing a significant decrease (*P<0.05) 2h after EMF exposure. Data normalized to 
α-tubulin and β2-microglobulin were expressed as difference (ΔΔCt) versus controls, then averaged for each 
experimental group. The columns control (CONTR, black) and EMF-exposed SC (EMF, white) were expressed as 
fold changes. The values are means ± S.D. (N = 3). (d) Accordingly, also the Nf2 protein levels were decreased 2 h 
following EMF exposure. Qualitative immunoblot (left panel) showing that the specific band for Nf2 (70 KDa) was 
downregulated in SCs. The α-tubulin (50 KDa) was used as a housekeeping protein. Quantitative data (right panel) 
confirmed a significant downregulation of Nf2/merlin at 2 h (*P < 0.05, white columns), while no changes were 
observed at 6 and 24 h. Experiments were normalized for α -tubulin, and expressed as percentage versus controls 
(CONTR, black columns). The values are means ± S.D. (N = 3). One-way ANOVA using Tukey's post-test was used 
for all statistical analysis. (e) Confocal images showed a different cellular distribution of Nf2/merlin. SCs were 
immunopositive for the specific markers P0 (red) and Nf2 (green). Merge images (yellow) revealed that merlin was 
more localized in the cytoplasm of EMF-exposed SCs, rather than in the nucleus (CONTR). Scale bar 10 µm. 
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ERK and AKT signaling pathways are activated in SCs following EMF exposure 
In order to identify possible pathways involved in SCs transformation and proliferation 
outcomes, ERK and AKT signaling were investigated. Both ERK 
(RAS/RAF/MEK/ERK) and AKT (PI3K/AKT) signaling pathways, which modulate 
biochemical pathways controlling cell growth and apoptosis, were activated. Western 
blot analysis confirmed that pERK significantly rose at 2 h (48,5%; P < 0.001), then 
significantly decreased at 6 h (53,3%; P < 0.001); tERK levels, indeed, showed a light 
but significant decrease at 2 h (21,9%; P < 0.05), then a significant increase at 6 h 
(83,4%; P < 0.001; Figure 24b). Analysis of pERK/tERK ratio confirmed that ERK 
signaling was activated at short time (+74,6%; 2 h), and deactivated within 6 h after 
EMF exposure (-78,3%; P < 0.001; Figure 24b). 
AKT analysis showed a similar trend of activation. Quantitative immunoblots analysis 
confirmed pAKT significant increase at 2 h (74,9%; P < 0.001), without changes 6 h 
after EMF exposure; tAKT levels were significantly augmented only 6 h after EMF 
exposure (51,3%; P < 0.001; Figure 24c). Analysis of pAKT/tAKT ratio showed a trend 
of AKT activation (even not significant) at short time (2 h), and AKT significant 
deactivation within 6 h after EMF exposure (-36,9%; P < 0.001; Figure 24c).  
Taken together these data corroborate an early activation of both signaling pathways, 
ERK and AKT, in controlling SCs proliferation, 2 h following EMF exposure. Both 
signaling pathways were turned off within 6 h following EMF exposure.  
  
115 
 
 
  
116 
 
Figure 24 ERK and AKT signaling pathways are activated in SCs following 10 min EMF exposure. (a) 
Representative immunoblots showing the variations in phosphorylated ERK 2 (pERK 2), total ERK 2 (tERK 2), both 
42 KDa, phosphorylated AKT (pAKT), total AKT (tAKT), both 60 KDa, in SCs at 2 and 6 h following EMF exposure. 
The β-actin (43 KDa) was used as a housekeeping protein. (b) Quantitative data at 2 h showed that pERK levels 
significantly increased (***P<0.001), while tERK levels decreased (*P<0.05); the pERK/tERK ratio showed that 
ERK signaling was activated 2h following EMF exposure (***P<0.001, white columns). Indeed, pERK levels 
significantly decreased at 6h (***P<0.001), while tERK significantly increased at 6 h (***P < 0.001); pERK/tERK 
ratio indicated that this signaling pathway was deactivated within 6 h following EMF exposure (***P<0.001). 
Experiments were normalized for β-actin, and expressed as percentage versus controls (CONTR, black columns). 
The values are means ±S.D. (N=3). (c) Quantitative data at 2h showing that pAKT levels significantly increased 
(***P<0.001), while tAKT levels were unchanged; the pAKT/tAKT ratio showed an activation trend, even not 
significant. At 6 h, pAKT levels did not change but tAKT levels were significantly rised (***P < 0.001); pAKT/tAKT 
ratio revealed a significant deactivation within 6 h after EMF exposure (***P < 0.001, white columns). Experiments 
were normalized for β-actin, and expressed as percentage versus controls (CONTR, black columns). The values are 
means ± S.D. (N = 3). One-way ANOVA using Tukey's post-test was used for all statistical analysis. 
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Dysregulation of the Hippo signaling pathway is a consequence of EMF exposure 
RT2 profiler PCR array was performed in order to study the possible involvement of 
Hippo pathway in SCs exposed to EMF. At least 21 genes that are upstream or 
downstream mediators of Hippo pathway, were found to be regulated. Bioinformatic 
analysis, however, revealed a downregulation of some of these genes, differently involved 
in the whole Hippo pathway (Figure 25a). More in detail, some proteins involved in cell 
polarity, such as Angiomotin like-2 (AMOTL2) and Crumbs homolog (CRB) protein 
complex (including proteins 1, 2 and 3), showed a decrease in gene expression levels 
(Figure 25b). As expected, Merlin expression was decreased, in accordance with qRT-
PCR and immunoblot results (Figures 23c and d). Other proteins, such as dachsous 
protein (DCHS, a member of transmembrane proteins belonging to the cadherin 
superfamily), transmembrane cadherin proteins (FAT) or proto-oncogen protein1 
(WNT1), involved in cell adhesion and myelinogenesis respectively, were also found to 
be changed (Figure 25b). 
On the basis of these results, the interest was focused on AMOTL2 and CRB (1, 2, 3), 
two proteins involved in cell morphologic rearrangements and polarity changes, as part 
of the tight-junction complex. Validation by qRT-PCR of the analysis previously 
performed in SC confirmed a significant downregulation (at least P < 0.05) of their 
expressions following EMF exposure (Figure 25c). We analyzed the transcriptional co-
activator YAP1, which is a downstream effector of Hippo pathway related to 
CRB/AMOTL tight junction was analyzed. The qRT-PCR analysis confirmed a 
significant downregulation (P < 0.001) of YAP1 in SCs after EMF exposure (Figure 
25d). Interestingly, YAP1 cellular localization was also changed. In control SCs, YAP1 
was localized mainly in the nucleus, supporting its physiologic activity in the control of 
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proliferation and apoptosis. In exposed SCs, indeed, YAP nuclear localization was 
diminished, being YAP1 mostly present in the cytoplasm (Figure 25e). In accordance, 
the absence of apoptosis in EMF-exposed SCs was strengthened by the lack of 
characteristic apoptotic nuclei, as observed by the IFL analysis (Figure 25e).  
Altogether these findings supported the involvement of Hippo pathway downstream to 
Merlin changes in SCs. This may be responsible of the YAP-mediated anti-apoptotic 
and proliferative effects observed on SCs (Figure 25f).  
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Figure 25 Hippo and YAP1 are altered in SCs at 2 h following EMF exposure. (a) Overview of the scatter plot of 
expression of 84 genes, related to the Hippo pathway, in which at least 21 genes were found to be changed 
(downregulated, green dots) in EMF-exposed SCs, versus controls (CONTR). The black line indicates fold changes 
(2−ΔΔCt) of 1. The dot lines indicate the desired fold change in gene expression threshold. Experiments were 
repeated at least three times, and normalized for β-actin (Actb), lactate dehydrogenase A (Ldha) and the 60S acidic 
ribosomal protein P1 (Rplp1). (b) Scheme of hierarchical clustering of normalized genes examined by RT2 profiler 
PCR array. Some genes coding for proteins involved in cell polarity, such as angiomotin like-2 protein (Amotl2) and 
Crumbs homolog proteins 1, 2 and 3 (Crb1, Crb2 and Crb3 respectively), as well as proteins involved in cell 
adhesion and myelinogenesis, such as dachsous proteins (Dchs), transmembrane cadherin proteins (Fat) or proto-
oncogen protein1 (Wnt1), showed a decreased expression following EMF exposure (green square), versus controls 
(CONTR, red square). Also Yes-associated protein 1 (Yap1) was found to be downregulated. (c) Amotl2, Crb1, 2 
and 3 gene expressions quantification was done by qRT-PCR, confirming a significant expression decrease following 
EMF exposure. Data were normalized to the housekeeping genes β-actin and Ldha, and expressed as difference 
(ΔΔCt) versus controls, then averaged for each experimental group. The columns control (CONTR, black) and EMF-
exposed SC (EMF, white) were expressed as fold changes. The values are means ±S.D. (N=3). One-way ANOVA 
using Tukey's post-test was used for statistical analysis. *P<0.05, **P<0.01. (d) Also Yap1 gene expressions 
quantification by qRT-PCR confirmed a significant decrease (***P<0.001) following EMF exposure. Data were 
normalized, calculated and repeated as described above. Control (CONTR, black column) and EMF-exposed SC 
(EMF, white column) were expressed as fold changes (means ±S.D.; N=3). (e) Confocal images showed a different 
cellular distribution of Nf2/merlin. SCs were immunopositive for the specific markers P0 (red) and Nf2 (green). 
Merge images (yellow) revealed that merlin was mostly localized in the cytoplasm of EMF-exposed SCs, rather than 
in the nucleus (CONTR). Scale bar 10 µm. (f) Model of the Hippo/Yap pathway involvement. In control SCs, Yap 
functions as tumor suppressor, assembling with Amotl2, Crb and merlin to maintain the tight junctions. In EMF-
exposed SCs, the tight-junction complex is disassembled and Yap is more localized in the cytoplasm. 
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Discussion 
Overall, these findings show that the tumor suppressor Nf2/Merlin is downregulated in 
SCs after the exposition to EMFs, leading to an altered morphology, proliferation, 
migration and SCs myelinating capability. These findings are associated with a 
consistent modulation of ERK/AKT and Hippo signaling pathways. In other words, SCs 
change their shape from spindle-shaped to an enlarged phenotype (Figure 21b), 
suggesting that EMFs alter their differentiation program.  
It is well known that during the differentiation SCs switch from flat into a spindle-
shaped phenotype, resembling the cells that start myelination process in vivo, which 
presents a reorganization of f-actin cytoskeleton and the appearance of the stress fiber 
bundles (Li et al., 2003). Therefore, the morphologic changes point to a SC de-
differentiation process. This phenomenon matches with a specific increase in cell 
proliferation (Figure 21d). It has been hypothesized that an autocrine growth factor 
and/or the translocation/recycling of membrane receptors may be responsible for the 
SC proliferation changes. Interestingly, in agreement with our previous observations 
the transport to the plasma membrane of GABA-B1 receptor and the neuronal excitatory 
amino acid transporter EAAC1/EAAT3, which localize in the elongated SC tips, 
appears to be associated with cytoskeleton rearrangements required for the GABAergic 
functionality in SCs (Perego et al., 2012; Procacci et al., 2012).  
The balance between proliferating and myelinating challenges in SCs may regulate their 
development toward the myelinating and/or the non-myelinating phenotype (Mirsky et 
al., 2008; Roberts and Lloyd, 2012). In this light, an increase in proliferation/migration 
probably correspond to a decrease in myelinating parameters. Moreover, the changes in 
P0 and PMP22 protein expressions levels, are in line with this hypothesis (Figures 23a 
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and b). Furthermore, the decrease in the proto-oncogene protein WNT1 (Figure 25b) 
fits with the diminished P0 and PMP22 levels (Tawk et al., 2011), corroborating the 
reversion in the myelinating program in the SC exposed to the EMF.  
The analysis of mRNA/protein levels, as well as the phosphorylation of ERK and AKT 
revealed an activation of this pathways (Figure 24), raising the possibility that EMF 
affects SC proliferation via mechanisms involving the ERK/AKT signaling pathways. 
This possibility agrees with previous observations obtained in schwannomas cells, 
where merlin is lost while the ERK pathway is activated (Pećina-Šlaus, 2013). 
Merlin is an important tumor suppressor factor, acting at the cell-to-cell tight junctions 
to allow the contact inhibition of growth, thus repressing proliferation (Das et al., 2015). 
Merlin was proved to inhibit mitogenic signaling by interacting with different target 
effectors at the cell membrane surface (McClatchey and Giovannini, 2005; Lallemand 
et al., 2009). The EMF ability to alter membrane integrity may cause tight-junctions 
remodeling, inducing mitogenic signals via ERK. The reduced levels of CRB and 
AMOTL (Figures 25b and c) suggest an impairment in tight-junction protein complex 
stability, entailing a dissociation of the AMOTL/Merlin complex (Figure 25f). If this 
holds true, merlin could relocates to the cytoplasm (Figure 25e), likely promoting ERK 
activation and cell proliferation, as demonstrated also by others (Morrison et al., 2007; 
Das et al., 2015). These findings suggest that the tight junctions are altered by EMFs, 
then leading to the loss of adhesion properties and to the increase in migrating capability 
(Figure 22). This is supported by the evidence that a disorganization in the cell 
membrane architecture abolishes the EMF effects on SCs migration (Figures 22c and 
d). Therefore, in line with the increased migrating capability in SCs, the decreased 
levels of Merlin may be predictive of the oncogenic transformation.  
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Evidence from the literature indicate that the Hippo pathway has a key role in the 
regulation of the tight-junction complex (Lacy-Hulbert et al., 1998). Interestingly, in 
this study was found an important modulation of the Hippo/YAP pathway in SCs. This 
contributes to the tight-junction complex and, when activated, it serves as tumor 
suppressor to limit cell growth. The dysregulation of the Hippo downstream effector 
YAP (Figure 25d), produces an increased cell proliferation and decreased 
differentiation (Plouffe et al., 2015), in line the results herein provided. It is also 
important to underline that AKT promotes YAP cytosolic localization, resulting in its 
loss from the nucleus (Basu et al., 2003). Interestingly, the increased AKT levels were 
associated with higher YAP immunopositivity in the cytoplasm (Figure 25e). 
In conclusion, a series of changes (i.e., tight-junction alterations, merlin decrease, SC 
migration, chemo-responsivity increase, YAP downregulation and redistribution), 
resulting into determining a reduction of the Hippo pathway were observed. All these 
changes are relevant for the control of SCs fate following 50 Hz-EMF exposure. 
Notably, the reduction of the oncosuppressor properties in SCs, resulting in an altered 
differentiation program, may be pathologically relevant for the schwannoma 
transformation. The identification of some altered mechanisms opens new questions on 
the exposure of SCs to the EMFs, although the fine identification of the intracellular 
signaling need further investigation. It is important to underline that although the 
therapeutic use of low-frequency (20Hz) EMFs has been proposed to promote 
peripheral nerve regeneration (Sisken et al., 1989; Sherafat et al., 2012), the 50 Hz 
frequency is commonly used in several medical devices for magnetotheraphy (Saliev et 
al., 2014; Yan et al., 2015) and in other electric devices. Unfortunately, when SCs are 
altered by EMF exposure, the risk to develop a neurofibroma might rise. The increasing 
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risk of the onset of vestibular schwannomas, coming from the long-term use of wireless 
phones, is still debated and needs further investigations, however, data from clinical 
case–control studies corroborate this pathogenic correlation (Hardell et al., 2006; Cardis 
and Schuz, 2011) and open new medical questions that need to be elucidated.  
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CHAPTER 3 
Transcriptomic profile of in vitro SCs and DRG neurons of 
GABA-B1 conditional knock out mice. 
GABA-B Rs are important for SCs control of myelination and for their commitment to 
a non-myelinating phenotype during development. Interestingly, the P0-Cre/GABA-
B1fl/fl mice presented also axon modifications, suggesting the existence of SC non-
autonomous effects mediated through the neuronal compartment. Other mechanisms, 
occurring in the neuronal compartment, may concur to the morphological and 
behavioural changes observed in the peripheral nerve of mice lacking GABA-B1 
specifically in SCs.  
Given these assumption, the studies summarized in this chapter pursue the aim 3 of this 
thesis that is to characterize in vitro the primary SCs and DRG neurons from P0-
Cre/GABA-B1fl/fl, analyzing also their whole trancriptome by Affimetrix GeneChip 
array. Particular interest has been focused on miRNAs analysis, because, as I mentioned 
in the Introduction, several papers showed fundamental roles for miRNAs in the control 
of development, differentiation, and health of myelinating cells of the mammalian 
nervous system (Dugas and Notterpek, 2011). 
Set up and characterization in vitro of the SCs and DRG neurons cultures from 
P0-Cre/GABA-B1fl/fl mice 
First, SCs and DRGs neurons cultures were characterized assessing the genotype and 
the positivity for some biochemical and morphological parameters. SCs were labelled 
with the specific antibody. P0, a typical marker for SCs, or S100, able to label both cells 
of neural origin and SCs in their first stage of development/differentiation. Phalloidin 
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was used to evaluate some differences in the actin citoskeleton rearrangement. As 
shown in Figure 26, SCs were immunopositive for P0 and for S100, the most important 
and characteristic marker of SCs. There were no evident morphologic differences 
between cells from P0-Cre/GABA-B1fl/fl (experimental) and GABA-B1fl/fl (control) 
mice. Moreover, there were no changes in cytoskeleton organization. This evidence 
suggested that SCs did not change their morphology, still possessing the capability 
proliferate and differentiate in vitro.  
DRG neurons were characterized, showing a good morphology in vitro. These cells 
were stained for S100, NF200 and CGRP, and no significant differences were found 
between the experimental and the control mice (Figure 27). To check whether the 
deletion of the GABA-B1 gene may affect SCs proliferation, viability and migration, 
several experiments were performed. The cell number was analysed under phase 
contrast light microscope, in presence of different concentration of the mitogen factor 
forskolin, generally known as cAMP inducer. This is in order to test whether the SCs 
from P0-Cre/GABA-B1fl/fl mice preserve basal proliferating characteristics. As shown in 
figure 28, the basal SCs from control mice, apparently increased when forskolin 
concentration was higher, changing from 2 to 10 µM. The morphology of SCs exposed to 
different forskolin concentrations: 2, 4, 10 and 100 µM was tested by IFL, using an antibody 
against P0 marker. The qualitative assessment of cell number (Figure 29) showed an 
increase in proliferation of SCs from conditional mice, depending on forskolin 
concentration. However, the quantitative proliferation assay revealed that SCs from 
experimental P0-Cre/GABA-B1fl/fl mice, at shorter time points (48 and 72 h), did not show 
any significant differences between 4 and 100 µM forskolin concentration (Figure 30). 
To assess the migratory capability of SCs a wound healing assay was performed in 
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presence of mytomicin-C 50 ng/mL, to block cell proliferation. SCs from experimental 
animal, showed a significant decrease in migration capability at 48 and 72 hours after 
treatment (Figure 31).  
 
Figure 26 SCs characterization. SCs were stained with Phalloidin they did not show any difference in the actin 
cytoskeleton. SCs were also immunopositive for S100 and for P0, the most important and characteristic marker of 
SCs. There are no evident differences between cells from P0-CRE/GABA-B1fl/fl experimental and GABA-B1fl/fl 
(control) mice. 
  
128 
 
 
Figure 27 DRG neurons characterization. DRG neurons were stained for S-100, for NF200 and CGRP, and also 
in this case, no significant differences were found between the experimental and the control mice. 
 
Figure 28 Picture from phase- contrast light microscope of SCs from GABA-B1fl/fl mice treated with two different 
concentration of forskolin (2 and 10 µM). 
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Figure 29 Exposure of SCs to different forskolin concentrations. SCs were exposed to several forskolin 
concentration: 2, 4, 10 and 100 µM. Differences in cell morphology were evaluated in immunofluorescence analysis 
using an antibody against P0 marker. 
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Figure 30 Proliferation assay on SCs from P0-Cre/GABA-B1 fl/fl and GABA-B1 fl/fl. SCs proliferation was assessed 
at 48 and 72 h, with two different fsk concentration (4 and 100 µM). In P0-Cre/GABA-B1 fl/fl mice SCs decrease in 
number, in all the condition considered (*P<0,001). Experiments were repeated at least three times and data 
expressed as cell number (×103). Two-way ANOVA using Bonferroni’s post hoc test was used for statistical analysis. 
 
Figure 31 Migratory capability of SCs performed with a wound healing assay. The distance between cells was 
measured with the Image-ProPlus software. As it shown in the graph, SCs from experimental animal, show a 
significant decreased in migration capability at 48 and 72 hours. 
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Transcriptomic analysis on SCs from P0-Cre/GABA-B1fl/fl mice  
The GABA-B1 receptor was further investigated by evaluating the transcriptomic 
expression profile of SCs and DRG neurons from P0-Cre/GABA-B1fl/fl mice. To this 
purpose, the transcriptomic profile was assessed by the Affimetrix GeneChip array 
technology. The results obtained from SCs and DRG neurons revealed that a 
considerable number of genes were modulated by the selective deletion of the GABA-
B1 receptor in the SCs (Figure 32). These data supported the importance of the cross-
regulation between SCs and neurons downstream the GABA-B1 activation in SCs. In 
particular, in SCs we observed changes in the expression of several genes coding for 
proteins involved in different pathway or intracellular signaling: cytokines, 
chemokines, proteins of the extracellular matrix, protein regulating cell proliferation, 
etc. About 41300 transcripts were analyzed, founding 2.66% (corresponding to 1099 
genes) differently expressed genes. The first set of 276 genes, were differently 
expressed in P0-Cre/GABA-B1fl/fl mice, with a gene expression level that was log2 
scaled. In particular, 38 downregulated and 238 upregulated genes in P0-Cre/GABA-
B1fl/fl mice (Figure 32), were worth of investigation. 
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Figure 32 Pairwise scatter plot Ctr vs GABA in SCs. The black lines are the boundaries of the 1-fold changes in 
gene expression levels between the paired samples. Gene up-regulated in ordinates samples compared with abscissas 
samples are shown in red circles; those down-regulated are shown in green. The positions of some markers are 
shown as orange dots. The color bar to the right indicates the scattering density, the higher is the scattering density 
the darker the blue. The gene expression levels are log2 scaled. 
 
Figure 33 Plot bar of the -log10(p) of the significant enriched terms of Ctr-<-GABA-Log2(2). The longer the bar, 
the higher is the statistical significance of the enrichment (in parenthesis are written the p-values). Transcriptomic 
expression profile of SCs cultures from P0-Cre/GABA-B1fl/fl (experimental) or GABA-B1fl/fl (control) mice by the 
Affimetrix GeneChip array technology (19). We analysed 41345 transcripts, founding 2.66% (corresponding to 1099 
genes) differently expressed genes. Then we focused on the first set of 276 genes, which are differently expressed in 
P0-Cre/GABA-B1fl/fl mice, with a gene expression level that was log2 scaled. We found 38 downregulated and 238 
upregulated genes in P0-Cre/GABA-B1fl/fl mice (20). 
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Transcriptomic analysis on DRG neurons from P0-Cre/GABA-B1fl/fl mice 
The same analysis was performed on DRG neurons revealing apparent changes in the 
expression of genes coding for proteins that control different intracellular signaling 
(Figure 34-35). In this case, the attention was focused on the first set of 59 genes, which 
were differently expressed in P0-Cre/GABA-B1fl/fl mice, with a gene expression level 
that was log2 scaled. In particular, 33 downregulated and 26 upregulated genes in P0-
Cre/GABA-B1fl/fl mice. Interestingly, these genes were related to the acetylcholine 
transmission pathway and the ion channels nicotinic receptors. Among nicotinic 
receptors, the expression of 3 fundamental subunits, respectively Chrna3, Chrnb3 and 
Chrnb4 were considered. Statistical analysis did not show any significant change in all 
the subunits studied (Figure 35), evidencing no substantial changes in DRG neurons of 
P0-Cre/GABA-B1fl/fl mice. 
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Figure 34 Pairwise scatter plot Ctr vs Exp in DRGs. The black lines are the boundaries of the 1-fold changes in 
gene expression levels between the paired samples. Gene up-regulated in ordinates samples compared with abscissas 
samples are shown in red circles; those down-regulated are shown in green. The positions of some markers are 
shown as orange dots. The color bar to the right indicates the scattering density, the higher is the scattering density 
the darker the blue. The gene expression levels are log2 scaled.  
 
Figure 35 Plot bar of the -log10(p) of the significant enriched terms of Ctr-<-Exp-Log2(2). The longer the bar, 
the higher is the statistical significance of the enrichment (in parenthesis are written the p-values) There were not 
statistically significantly enriched terms in this category. 
MiR-338-3p is modulated in SCs of P0-Cre/GABA-B1fl/fl mice: qRT-PCR and 
in silico analysis 
Transcriptomic analysis showed that some miRNAs were up- or downregulated in P0-
Cre/GABA-B1fl/fl mice. Namely, the analysis was focused on miR-338, which has been 
implicated in SC differentiation (Zhao et al., 2010; Gokey et al., 2012). First, miR-338 
expression was confirmed in SCs cultures from both P0-CRE/GABA-B1fl/fl and GABA-
B1fl/fl mice, finding a significant downregulation (*P<0,01) of the miR-338 3p segment 
(miR-338-3p), while the 5p segment did not change (Figure 36). 
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Figure 36 mRNA expression of miR-338-3p. Relative quantification by qRT-PCR of mRNA levels, coding for mir-
338-3p showed a decreased expression in P0-Cre/GABA-B1fl/fl mice. Data were normalized to the housekeeping 
genes hsa-103 and expressed as difference (ΔΔCt) versus WT. The WT column (black) and P0-Cre/GABA-B1fl/fl 
(white) were expressed as fold changes. The values are means ± S.D. (N = 3). **P < 0.01 
 
Then, to investigate the potential role of miR-338-3p, an in silico analysis was 
performed on the mouse MyMIR databases. A list of 729 putative target transcripts of 
miR-338-3p in mouse was found. Thereafter, STRING, a Gene Ontology (GO) based 
tools, showed that these targets were significantly clustered in 3 principal pathways: 
“Biological process” (BP), “Molecular function” (MF), “Cellular compartment” (CC).  
Biological process, suggesting that miR-338-3p takes part in their regulation. We found 
that the main GO biological pathways involved were: nervous system development, 
anatomical structure morphogenesis, signal transduction, intracellular signaling 
transduction, synaptic transmission and cell-cell signaling. For all of these biological 
processes the fold enrichment in miR-338-3p targets was calculated  using the following 
formula: 
Fold enrichment= 
!÷#$÷% 
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m = genes target in a BP; n =all genes target in the list; M = all genes in a BP; N = all 
genes in the genoma (see Figure 37). 
 
 
Figure 37 Gene Ontology biological processes (GO BPs) related to SC development are enriched in miR-338-3p 
targets. Histograms show the significant GO BPs enriched in miR-338-3p target transcripts (Fold enrichment 
compared to expected value=1; see left axis). Dots represent p-value (with FDR correction) of the prediction for 
each GO BP (see right axis; log10 scale). 
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Discussion 
In the last decades the role of the neurotransmitters, such as GABA, in the control of 
neuron-glia cell interaction in the PNS received great attention (Fields and Burnstock, 
2006; Loreti et al., 2007). With particular attention to the PNS, the study of total GABA-
B1 -/- mice (total null mice) showed biochemical, anatomical and functional changes. 
Indeed, with morphological and molecular alterations in myelin as well as an increased 
number of small caliber axons and small DRG neurons was observed. These mice 
revealed also changes in sensory nociceptive functions (Magnaghi et al., 2008a). 
Successively, the role of the GABA-B1 receptor PNS myelination was tested by the 
specific inactivation of the receptor only in SCs, demonstrating SC-autonomous effects. 
However, further studies showed signs of SC degeneration, such as tomacula, fractured 
myelin, and partial or complete uncompaction of myelin. In line with these results, also 
the percentage of fibers with irregular profile, an index of myelin dysregulation, was 
strongly augmented (Faroni et al., 2014a). Overall, these effects were considered SC-
non-autonomous. Therefore, in order to investigate the involvement of SCs on DRG 
neurons in the nerve features occurring following GABA-B1inactivation, we performed 
the present study. 
First, the SCs and DRG neurons cultures were characterized with specific antibodies. 
No differences between P0-Cre/GABA-B1fl/fl and GABA-B1fl/fl mice, were found 
demonstrating that the GABA-B1 receptor selective deletion in SCs has no influences 
on SCs morphology and on the DRG neurons morphology.  
The exposure to different forskolin concentrations apparently increases SC 
proliferation in control mice. However, the quantitative analysis of SCs number 
from the P0-Cre/GABA-B1fl/fl mice showed a decrease in proliferation with no 
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significant differences between the different concentrations considered (Figure 30). 
Indeed, the migration capability, in the conditional knock out mice was significantly 
diminished (Figure 31).  
Taken together, these findings evidenced the possibility that the GABA-B1 deletion in 
SCs induces some modification in the mRNA expression profile of the same cells, in 
turn able to produce changes in functional features, like proliferation and migration. 
To assess these hypothesis, we did several transcriptomic analyses on SCs and DRG 
neurons cultures obtained from these animals, to shed light on the possible changes in 
mRNA expression levels of different genes that regulate the functional changes. In 
particular the Affymetrix GeneChip array technology changes in SCs. In these cells, we 
observed changes in the expression level of several genes coding for protein like 
cytokines, chemokines, proteins of the extracellular matrix, protein regulating cell 
proliferation. Interestingly, among these genes, there are different miRNA that are down 
or upregulated in SCs cultures from P0-Cre/GABA-B1fl/fl.  
The miRNAs are involved in post-transcriptional regulation of different genes in 
different type of cells, controlling physiological processes and determining pathological 
condition (Dugas and Notterpek, 2011). 
It is also remarkable that some miRNAs are induced during differentiation (miR-219, 
-338, -138) and some other are high in pre-myelinating SCs and OL but then decrease 
during myelination (Svaren, 2014). Moreover, at least in SCs, some of this miRNAs 
rebound after peripheral nerve injury (Viader et al., 2011b; Adilakshmi et al., 2012; 
Yu et al., 2012).  
Microarray analysis identified a series of miRNAs that are developmentally regulated 
during maturation of SCs (Bremer et al., 2010b; Pereira et al., 2010; Yun et al., 2010; 
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Gokey et al., 2012). Our results show that miRNA-338 is modulated in SCs cultures 
from P0-CRE/GABA-B1fl/fl, in line with the recent literature that demonstrates the 
involvement of mir-338 in the OL and SCs differentiation process. These preliminary 
results were validated by qRT-PCR analysis so that and the future perspective is to silence 
mir-338 and evaluate different cell parameters, such as the expression of characteristic 
proteins involved in the maturation/differentiation on development of SCs. 
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Conclusion 
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In this thesis are described different lines of research pursued during my PhD program. 
These studies were aimed to the investigation of three distinct and interplaying 
pathways, that have a role in the maturation and myelination processes of SCs.  
In the first part of this work, it was studied the molecular mechanism of ALLO actions 
in SCs, elucidating the role of the SRC/FAK pathways. ALLO modulation of the SRC 
and p-FAK pathways involves GABA-A R mediated mechanisms. ALLO and 
SRC/FAK determine SC actin remodeling, controlling SC motility and morphological 
changes, beside proliferation and myelination. These findings supported the 
comprehension of the GABA-A R role in the PNS myelination process and demonstrate 
that ALLO and the GABAergic system are a promising tool for the treatment of PNS 
disorders.  
Regarding the second part, it was demonstrated that SCs exposed to EMF change their 
characteristic features, under the control of the Hippo pathway. The tumor suppressor 
Nf2/Merlin, upstream the Hippo pathway, is downregulated in exposed SCs, 
determining alterations in proliferation, migration, morphology and myelination 
capability. These evidences open an important discussion on the use of EMFs in 
regenerative medicine and emphasise the exposition to EMFs, which may represent a 
common but risky challenge for the nervous system. Notably, the reduction of Nf2 
oncosuppressor, following EMF exposure, results in altered cell differentiation 
program, that may be pathologically relevant for the schwannoma transformation. 
Lastly, in the third part of this work, it was also studied the relevance of transcriptional 
modifications on SCs following GABA-B1 deletion. GABA-B1 R conditional knock 
out mice showed alterations in myelinating capability. The transcriptomic expression 
profile was assessed showing a deregulation in many genes involved in primary 
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biological processes of SCs. Among these, an important issue may be represented by 
miRNAs. Particularly, miR-338-3p, known to be involved in CNS myelination, was 
an interesting target for the study of the myelination process under GABA-B R 
control. In fact, it was found, at least in silico, that miR-338-3p targets many genes 
involved in myelination.  
Altogether, our findings shed light on novel, important and promising pathways 
involved in SC functions and PNS myelination. Hopefully, they contribute to deepen 
the knowledge of the mechanisms responsible of inherited and acquired PN, in order to 
find new and reliable therapeutic approaches for these pathologies. 
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